Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 11, 2017
ROSELAND, N.J., Aug. 11, 2017 (GLOBE NEWSWIRE) -- The Board of Directors of Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that the Company intends to voluntarily terminate its reporting obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Accordingly, the Company intends to file a Form 15 with the Se...
May 12, 2017
ROSELAND, N.J., May 12, 2017 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the first quarter ended March 31, 2017, and how to access today's quarterly earnings call where the management team will overview recent progress against the Company's business plan.  FIRST QUARTER 2017 FINANCIAL RE...
May 4, 2017
ROSELAND, N.J., May 04, 2017 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the first three months ended March 31, 2017, on Friday, May 12, 2017 at 8:30 AM ET. A press release will be issued prior to market ope...
May 3, 2017
ROSELAND, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the first three months ended March 31, 2017, on Friday, May 12, 2017. A press release will be issued prior to market open. The li...
Mar 29, 2017
ROSELAND, N.J., March 29, 2017 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the fourth quarter and full fiscal year ended December 31, 2016, and provided an overview of corporate accomplishments and plans. "The last twelve months have been a pivotal time for Emisphere," said Alan L. Rubin...
Mar 21, 2017
ROSELAND, N.J., March 21, 2017 (GLOBE NEWSWIRE) -- Emisphere (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the twelve months ended December 31, 2016, on Wednesday, March 29, 2017, at 8:30 AM ET. A press release will be issued prior to market open. The l...
Dec 9, 2016
ROSELAND, N.J., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that it has reached agreement with MHR Fund Management LLC, and certain of its affiliated funds ("MHR") to waive certain of the terms of the Company's existing obligations under the loan facility and various promissory notes previously issu...
Nov 14, 2016
ROSELAND, N.J., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the third quarter ended September 30, 2016, and provided an overview of corporate accomplishments and plans. "To date in 2016, we have made significant progress toward our key corporate objectives of securing a strat...
Nov 7, 2016
ROSELAND, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the three months ended September 30, 2016, on Monday, November 14, 2016, at 8:30 AM ET. A press release will be issued prior to marke...
Aug 15, 2016
ROSELAND, N.J., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the second quarter ended June 30, 2016, and provided an overview of corporate accomplishments and plans. "During the first half of 2016, we continued to focus our efforts on business development initiatives, includ...
Aug 8, 2016
ROSELAND, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the three months ended June 30, 2016, on Monday, August 15, 2016, at 8:30 AM ET. A press release will be issued prior to market open....
May 16, 2016
ROSELAND, N.J., May 16, 2016 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the quarter ended March 31, 2016, and provided an overview of corporate accomplishments and plans. "During the first quarter 2016, on the commercial side of our business, we continued to focus on building new, high ...
May 9, 2016
ROSELAND, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Emisphere (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the three months ended March 31, 2016, on Monday, May 16, 2016, at 8:30 AM ET. A press release will be issued prior to market open. The live webcast...
Mar 29, 2016
ROSELAND, N.J., March 29, 2016 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the fourth quarter and full fiscal year ended December 31, 2015, and provided an overview of corporate accomplishments and plans. "The last twelve months have been a pivotal time for Emisphere," said Alan L. Rubin...
Mar 24, 2016
ROSELAND, N.J., March 24, 2016 (GLOBE NEWSWIRE) -- Emisphere (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the twelve months ended December 31, 2015, on Tuesday, March 29, 2016, at 8:30 AM ET. A press release will be issued prior to market open. The live ...
Nov 16, 2015
ROSELAND, N.J., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the third quarter ended September 30, 2015, and provided a corporate update. "During the third quarter, we made great strides in commercializing the Eligen® technology.  There were two important developments w...
Nov 10, 2015
ROSELAND, N.J., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that Management will host a conference call on Monday, November 16, 2015, at 8:30 AM ET to discuss the Company's financial and operational results for the third quarter ended September 30, 2015. The live webcast of the conference call ...
Nov 5, 2015
ROSELAND, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that President and Chief Executive Officer, Alan L. Rubino, will present at the SeeThruEquity MicroCap Investor Forum at 9:30 AM ET on Thursday, November 12, 2015. The SeeThruEquity conference is being held at the Convene Grand Central in N...
Oct 15, 2015
ROSELAND, N.J., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. today announced that it has entered into a Development and License Agreement with Novo Nordisk A/S (NYSE:NVO) to develop and commercialize oral formulations of four classes of Novo Nordisk's investigational molecules targeting major metabolic disorders, including diabe...
Sep 2, 2015
ROSELAND, N.J., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that President and Chief Executive Officer, Alan L. Rubino, will present at the Rodman and Renshaw 17th Annual Global Investment Conference at 9:35 AM ET on Wednesday, September 9, 2015. The Rodman and Renshaw conference is being held at The ...
Aug 26, 2015
ROSELAND, N.J., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today highlighted that Eligen® licensee Novo Nordisk A/S (NYSE:NVO) will initiate a global phase 3a development program with oral semaglutide, a once daily oral formulation of the long-acting GLP-1 analogue semaglutide, for the treatment of type 2 diabe...
Aug 12, 2015
ROSELAND, N.J., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the quarter ended June 30, 2015, and provided a corporate update. "During the second quarter, we continued to execute on the U.S. commercial launch of oral Eligen B12™ Rx, the first oral prescription product...
Aug 6, 2015
ROSELAND, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that Management will host a conference call on Wednesday, August 12, 2015, at 8:30 AM ET to discuss the Company's financial and operational results for the second quarter ended June 30, 2015. The live webcast of the conference call can...
May 15, 2015
ROSELAND, N.J., May 15, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the first quarter ended March 31, 2015, and provided an overview of corporate accomplishments and plans. "The execution of our U.S. commercial launch of Eligen B12™ is underway and we believe our current reso...
May 11, 2015
ROSELAND, N.J., May 11, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call on Friday, May 15, 2015, at 8:30 AM EDT to discuss the Company's financial and operational results for the quarter ended March 31, 2015. The live webcast of the conference call can be accesse...
Mar 31, 2015
Recent Launch of Eligen B12™ Marks Company's Expansion into Commercializing Practical Innovation Management to Host Conference Call Today at 8:30 AM ET ROSELAND, N.J., March 31, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the fourth quarter and full fiscal year ended...
Mar 25, 2015
ROSELAND, N.J., March 25, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call on Tuesday, March 31, 2015, at 8:30 AM ET to discuss the Company's financial and operational results for the quarter and twelve months that ended December 31, 2014. The live webcast of the ...
Mar 19, 2015
ROSELAND, N.J., March 19, 2015 /PRNewswire/ -- Emisphere Technologies, Inc. (OTCBB: EMIS) today announced the U.S. commercial availability of Eligen B12™, the first and only once-daily oral prescription medical food tablet shown to normalize B12 levels without the need for an injection. Eligen B12 is indicated for the dietary management of pa...
Feb 20, 2015
ROSELAND, N.J., Feb. 20, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today highlighted positive Phase 2 data from Eligen® licensee Novo Nordisk pertaining to OG217SC, the oral formulation of semaglutide, a long-acting human GLP-1 analogue that stimulates insulin and suppresses glucagon secretion in a glucose-dependent ma...
Nov 14, 2014
ROSELAND, N.J., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended September 30, 2014. The Company will host a conference call this morning at 8:30 AM ET to discuss these results. The live webcast of the conference call can be...
Nov 12, 2014
ROSELAND, N.J., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended September 30, 2014 on Friday, November 14, 2014 at 8:30 AM ET. A press release will be issued pr...
Aug 20, 2014
ROSELAND, N.J., Aug. 20, 2014 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced that it has reached agreement with MHR Fund Management LLC, and certain of its affiliated funds ("MHR"), to finance the upcoming launch of the Company's first commercial prescription product, oral Eligen® B...
Aug 14, 2014
ROSELAND, N.J., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended June 30, 2014. The Company will host a conference call on Thursday, August 14, at 8:30 AM ET to discuss these results. The live webcast of the conference call ...
Aug 13, 2014
ROSELAND, N.J., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended June 30, 2014 on Thursday, August 14, 2014 at 8:30 AM ET. A press release will be issued prior t...
May 14, 2014
ROSELAND, N.J., May 14, 2014 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended March 31, 2014. The Company will host a conference call this morning at 8:30 AM ET to discuss these results. The live webcast of the conference call can be acce...
May 12, 2014
ROSELAND, N.J., May 12, 2014 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended March 31, 2014 on Wednesday, May 14, 2014 at 8:30 AM ET. A press release will be issued prior to ...
Mar 31, 2014
ROSELAND, N.J., March 31, 2014 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the fourth quarter and year ended December 31, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results. The live webcast of the confer...
Mar 28, 2014
ROSELAND, N.J., March 28, 2014 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that Management will host a conference call to discuss the Company's financial and operational results for the twelve months ended December 31, 2013 on Monday, March 31, 2014 at 8:30 AM ET. A press release will be issued prio...
Nov 12, 2013
ROSELAND, N.J., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended September 30, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results. The live webcast of the conference call can be...
Nov 8, 2013
ROSELAND, N.J., Nov. 8, 2013 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the third quarter ended September 30, 2013 on Tuesday, November 12, 2013 at 8:30 AM ET. A press release will be issued p...
Aug 13, 2013
ROSELAND, N.J., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended June 30, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results. The live webcast of the conference call can be acce...
Aug 8, 2013
ROSELAND, N.J., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the second quarter ended June 30, 2013 on Tuesday, August 13, 2013 at 8:30 AM ET. A press release will be issued prior t...
May 15, 2013
ROSELAND, N.J., May 15, 2013 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the quarter ended March 31, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results. The live webcast of the conference call can be acce...
May 13, 2013
ROSELAND, N.J., May 13, 2013 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the first quarter ended March 31, 2013 on Wednesday, May 15, 2013 at 8:30 AM ET. A press release will be issued prior to...
Apr 29, 2013
ROSELAND, N.J., April 29, 2013 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced that it has reached agreement with MHR Fund Management LLC and its various affiliated funds (collectively "MHR") to restructure the terms of its obligations under various promissory notes issued to MHR. ...
Apr 29, 2013
ROSELAND, N.J., April 29, 2013 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that it has agreed with Novo Nordisk A/S (NYSE:NVO) to amend the two companies' Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists, which have the potential ...
Mar 28, 2013
ROSELAND, N.J., March 28, 2013 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company") today announced its financial results for the fourth quarter and year ended December 31, 2012. The Company plans to host a conference call in the future to provide a Company-wide update on the status of the business. F...
Nov 13, 2012
CEDAR KNOLLS, N.J., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) (the "Company") today announced its financial results for the quarter and year to date ended September 30, 2012. The Company will host a conference call this morning at 10:00 AM EST to discuss these results. The live webcast of the conference cal...
Nov 9, 2012
CEDAR KNOLLS, N.J., Nov. 9, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the third quarter ended September 30, 2012 on Tuesday, November 13, 2012 at 10:00 AM ET. A press release will be iss...
Sep 26, 2012
CEDAR KNOLLS, N.J., September 26, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) (the "Company") announced today that, as of September 27, 2012, the Company will be in default under the terms of the Company's 11% Senior Secured Convertible Notes (the "Senior Secured Convertible Notes") issued to MHR Fund Management LLC (together...
Sep 17, 2012
CEDAR KNOLLS, N.J., Sept. 17, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) (the "Company") announced the appointment of Alan L. Rubino to the position of President and Chief Executive Officer, effective immediately. Mr. Rubino has also been elected to the Company's Board of Directors. "Alan is a seasoned industry executive wit...
Aug 7, 2012
CEDAR KNOLLS, N.J., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) (the "Company") today announced its financial results for the quarter and year to date ended June 30, 2012. The Company will host a conference call this morning at 10:00 AM EDT to discuss these results. The live webcast of the conference call can ...
Aug 2, 2012
CEDAR KNOLLS, N.J., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the second quarter ended June 30, 2012 on Tuesday, August 7, 2012 at 10:00 AM ET. A press release will be issued pri...
May 9, 2012
CEDAR KNOLLS, N.J., May 9, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) (the "Company") today announced its financial results for the quarter ended March 31, 2012. The Company will host a conference call this morning at 10:00 AM EDT to discuss these results. The live webcast of the conference call can be accessed throu...
May 4, 2012
CEDAR KNOLLS, N.J., May 4, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the first quarter ended March 31, 2012 on Wednesday, May 9, 2012 at 10:00 AM ET. A press release will be issued prior to market open....
Mar 21, 2012
CEDAR KNOLLS, N.J., March 21, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced its financial results for the fourth quarter and year ended December 31, 2011. The Company will host a conference call this morning at 10:00 AM EDT to discuss these results. The live webcast of the conference call can be accessed...
Mar 15, 2012
CEDAR KNOLLS, N.J., March 15, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the fourth quarter and year ended December 31, 2011 on Wednesday, March 21, 2012 at 10:00 AM ET. A press release will be issued pr...
Mar 1, 2012
CEDAR KNOLLS, N.J., March 1, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that Tim McInerney, a Principal at Two River Group Holdings and a Partner of Riverbank Capital Securities, Inc., and Jacob Plotsker, Senior Director, Commercial Operations for Teva Pharmaceuticals Women's Health Division, have been appoin...
Dec 14, 2011
CEDAR KNOLLS, N.J., Dec. 14, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) ("Emisphere" or the "Company") announced today that Novartis Pharma AG ("Novartis") has informed the Company that it will not pursue further clinical development of the investigational drug SMC021 (oral calcitonin) being studied by Nordic Bioscience (the...
Nov 14, 2011
CEDAR KNOLLS, N.J., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) ("Emisphere" or the "Company") announced today that it has been informed by Novartis Pharma AG ("Novartis") that Novartis has released first interpretable results (FIR) from its three-year Phase III Study 2303 assessing the safety and efficacy of oral ca...
Nov 8, 2011
CEDAR KNOLLS, N.J., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB: EMIS) announced its financial results for the third quarter 2011. The Company will host a conference call this morning at 10:00 AM ET to discuss these results. The live webcast of the conference call can be accessed through the company's web site at: w...
Nov 3, 2011
CEDAR KNOLLS, N.J., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the third quarter ended September 30, 2011 on Tuesday, November 8, 2011 at 10:00 AM ET. A press release will be issued prior to mark...
Oct 13, 2011
CEDAR KNOLLS, N.J., Oct. 13, 2011 (GLOBE NEWSWIRE) -- On July 23, 2010 Emisphere Technologies, Inc. (OTCBB:EMIS) reported that Novartis Pharma AG ("Novartis") and its license partner Nordic Bioscience A/S ("Nordic Bioscience") provided certain information in connection with their Phase III Study 2302 assessing the safety and efficacy of oral calcit...
Aug 9, 2011
CEDAR KNOLLS, N.J., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) announced its financial results for the second quarter 2011. The Company will host a conference call this morning at 10:00 AM EDT to discuss these results. The live webcast of the conference call can be accessed through the company's web site at: ...
Aug 4, 2011
CEDAR KNOLLS, N.J., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the second quarter ended June 30, 2011 on Tuesday, August 9, 2011 at 10:00 AM EDT. A press release will be issued prior to market op...
Jun 30, 2011
CEDAR KNOLLS, N.J., June 30, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (the "Company") (OTCQB:EMIS) today announced that it has entered into a securities purchase agreement with certain institutional investors pursuant to which the Company has agreed to sell an aggregate of approximately 4.3 million shares of its common stock and warran...
Jun 17, 2011
CEDAR KNOLLS, N.J., June 17, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that Novartis informed Emisphere of the results of its recently completed Proof of Concept study for an oral PTH1-34 using Emisphere's Eligen® Technology in post-menopausal women with osteoporosis or osteopenia. Novartis informed Emi...
May 10, 2011
CEDAR KNOLLS, N.J., May 10, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced its financial results for the first quarter 2011. The Company will host a conference call this morning at 10:00 AM EDT to discuss these results. The live webcast of the conference call can be accessed through the company's web site at: w...
May 6, 2011
CEDAR KNOLLS, N.J., May 6, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the First Quarter ended March 31, 2011 on Tuesday, May 10, 2011 at 10:00 AM EDT. A press release will be issued prior to market open....
Mar 31, 2011
CEDAR KNOLLS, N.J., March 31, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced its financial results for the fourth quarter and year ended December 31, 2010. The Company will host a conference call this morning at 10:00 AM EDT to discuss these results. The live webcast of the conference call can be accessed...
Mar 30, 2011
CEDAR KNOLLS, N.J., March 30, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the Fourth Quarter and Year Ended December 31, 2010 on Thursday, March 31, 2011 at 10:00 AM EDT. A press release will be issued pr...
Mar 14, 2011
CEDAR KNOLLS, N.J., March 14, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that it has postponed its conference call to discuss financial results for the fourth quarter and year ended December 31, 2010. The conference call was originally scheduled for Tuesday, March 15, 2011 at 10:00 AM EDT. The Company decided...
Mar 8, 2011
CEDAR KNOLLS, N.J., March 8, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the Fourth Quarter and Year Ended December 31, 2010 on Tuesday, March 15, 2011 at 10:00 AM EDT. A press release will be issued prio...
Feb 28, 2011
CEDAR KNOLLS, N.J., Feb. 28, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that the Company and Michael V. Novinski have come to a mutual agreement not to renew Mr. Novinski's employment agreement with the Company. In connection with this mutual agreement not to renew the employment agreement, Mr. Novinski resig...
Feb 17, 2011
Dec 21, 2010
CEDAR KNOLLS, N.J., Dec. 21, 2010 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) and Novo Nordisk A/S (NYSE:NVO) today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emi...
Nov 12, 2010
CEDAR KNOLLS, N.J., Nov. 12, 2010 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that the Michael V. Novinski, President and Chief Executive Officer will present at the Maxim Group Growth Conference in New York City on Thursday, November 18, 2010 at 2:00 PM. The conference will be held at the Grand Hyatt New York Hote...
Nov 10, 2010
CEDAR KNOLLS, N.J., Nov. 10, 2010 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced financial and operational results for the three and nine months ended September 30, 2010. THIRD QUARTER FINANCIAL RESULTS For the three months ended September 30, 2010, Emisphere reported net income of $9.6 million, or $0....
Nov 4, 2010
CEDAR KNOLLS, N.J., Nov. 4, 2010 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the Third Quarter 2010 on Thursday, November 11, 2010 at 10:00 AM EST. A press release will be issued prior to market open. ...
Oct 22, 2010
CEDAR KNOLLS, N.J., Oct 22, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that Novartis Pharma AG ("Novartis") provided Emisphere with information regarding the First Interpretable Results of the two-year Phase III Study 2301 in osteoarthritis conducted by its license partner Nordic Biosci...
Sep 17, 2010
CEDAR KNOLLS, N.J., Sep 17, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that a clinical study found that the company's proprietary oral SNAC (Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate ("SNAC") additive, in combination with two digestive hormones, was successful in reducing food int...
Sep 7, 2010
CEDAR KNOLLS, N.J., Sep 7, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen(R) Technology, today announced that President and Chief Executive Officer, Michael V. ...
Aug 25, 2010
CEDAR KNOLLS, N.J., Aug 25, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that on August 25, 2010, Emisphere Technologies, Inc. (the "Company") entered into a securities purchase agreement with certain institutional investors pursuant to which the Company has agreed to sell an aggregate of...
Aug 16, 2010
CEDAR KNOLLS, N.J., Aug 16, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced financial and operational results for the three and six months ended June 30, 2010. SECOND QUARTER FINANCIAL RESULTS For the three months ended June 30, 2010, Emisphere reported a net loss of $13.7 million, o...
Aug 9, 2010
Aug 9, 2010 (GlobeNewswire via COMTEX News Network) -- Conference Call/Webcast to be Held Monday, August 16, 2010 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug. 9, 2010 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Com...
Jul 23, 2010
CEDAR KNOLLS, N.J., Jul 23, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that Novartis Pharma AG and its license partner Nordic Bioscience a/s (the "Sponsor") have reported the following in connection with their Phase III Study 2302 in osteoarthritis assessing the safety and efficacy of o...
Jul 16, 2010
CEDAR KNOLLS, N.J., Jul 16, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that it is engaged in ongoing discussions with a potential licensee for its high dose oral Eligen(R) B12 1000mcg as a Medical Food for individuals with B12 deficiency. In addition, the Company is evaluating other pot...
Jun 4, 2010
CEDAR KNOLLS, N.J., Jun 4, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) (the "Company") today announced that it has entered into an expanded relationship with Novartis Pharma AG ("Novartis") pursuant to which Novartis has cancelled the Company's Convertible Promissory Note (the "Note"). The Note was orig...
May 27, 2010
CEDAR KNOLLS, N.J., May 27, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen(R) Technology, today announced that Novartis Pharma AG has agreed to further extend...
May 18, 2010
CEDAR KNOLLS, N.J., May 18, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host its Annual Meeting of Shareholders on Tuesday, May 25, 2010 at 10:00 AM EDT. The meeting will be held at the Park Avenue Club, 184 Park Avenue, Florham, Park, NJ. About Emisphere Technol...
May 17, 2010
CEDAR KNOLLS, N.J., May 17, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced its financial results for the first quarter 2010. The Company will host a conference call to discuss financial results at 10:00 AM EDT this morning. The live webcast of the conference call can be accessed through...
May 10, 2010
CEDAR KNOLLS, N.J., May 10, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the first quarter of 2010 on Monday, May 17, 2010 at 10:00 AM EDT. A press release will be issued prior to ma...
Apr 29, 2010
CEDAR KNOLLS, N.J., Apr 29, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that interim data from an ongoing study demonstrated that its high-dose oral Eligen(R) B12 (1000mcg) given to individuals with low B12 levels restores normal B12 serum concentrations. Normal levels of serum B12 were ...
Apr 26, 2010
CEDAR KNOLLS, N.J., Apr 26, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today the publication of a research study entitled, "Investigation of the Direct Effect of Salmon Calcitonin on Human Osteoarthritic Chondrocytes," by Nordic Bioscience in the April 5, 2010 edition of the publication BMC M...
Apr 15, 2010
CEDAR KNOLLS, N.J., Apr 15, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that Novartis Pharma AG has initiated a second Phase I trial for an oral PTH1-34 which uses Emisphere's Eligen(R) Technology, and is in development for the treatment of postmenopausal osteoporosis. Emisphere Technolo...
Mar 25, 2010
CEDAR KNOLLS, N.J., Mar 25, 2010 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTCBB: EMIS) today announced its financial results for the fourth quarter and year ended December 31, 2009. The Company will host a conference call to discuss the results at 10:00 AM EDT Thursday, March 25, 2010. The live webcast of the confer...
Mar 18, 2010
CEDAR KNOLLS, N.J. & BRISBANE, Australia, Mar 18, 2010 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) today announced that they are joining efforts to develop an oral formulation of the anti-coagulant drug fondaparinux with Emisphere's Eligen(R) Technology. Emisphere's broad-based d...
Mar 17, 2010
CEDAR KNOLLS, N.J., Mar 17, 2010 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the fourth quarter and year ended December 31, 2009 on Thursday, March 25, 2010 at 10:00 AM EDT. A press ...
Feb 24, 2010
CEDAR KNOLLS, N.J., Feb 24, 2010 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen(R) Technology, today announced that Novartis Pharma AG has agreed to furt...
Feb 2, 2010
CEDAR KNOLLS, N.J., Feb 02, 2010 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen(R) Technology, today announced that President and Chief Executive Officer, Michael V. Novinski, will present at ...
Jan 13, 2010
CEDAR KNOLLS, N.J., Jan 13, 2010 (BUSINESS WIRE) -- Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen(R) Technology is used in ...
Dec 21, 2009
CEDAR KNOLLS, N.J., Dec 21, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin. This publication restates the potential of ca...
Dec 10, 2009
CEDAR KNOLLS, N.J., Dec 10, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that an independent Data Monitoring Committee ("DMC") informed Novartis and its partner Nordic Bioscience about their recommendation to proceed with the Osteoporosis ("OP") Phase 3 Study 2303 and the Osteoarthritis ...
Nov 30, 2009
CEDAR KNOLLS, N.J., Nov 30, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen(R) Technology, today announced that Novartis Pharma AG has agreed to extend ...
Nov 24, 2009
CEDAR KNOLLS, N.J., Nov 24, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen(R) Technology, today announced that President and Chief Executive Officer, Michael ...
Nov 9, 2009
CEDAR KNOLLS, N.J., Nov 09, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced financial and operational results for the third quarter and nine months ended September 30, 2009. THIRD QUARTER FINANCIAL RESULTSFor the three months ended September 30, 2009, Emisphere reported a net loss of $4.0...
Nov 5, 2009
CEDAR KNOLLS, N.J., Nov 05, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that Tim Rothwell, former Chairman of Sanofi-aventis U.S., has been appointed to the Company's Board of Directors effective immediately. Mr. Rothwell's appointment fills the vacancy created by Franklin Berger, who r...
Nov 4, 2009
CEDAR KNOLLS, N.J., Nov 04, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the third quarter ended September 30, 2009 on Monday, November 9, 2009 at 10:00 AM EST. A press release ...
Nov 2, 2009
CEDAR KNOLLS, N.J., Nov 02, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that interim data from an ongoing study demonstrated its high-dose oral Eligen(R) B12 (1000mcg) performed as well as or better than B12 injections in individuals with Vitamin B12 deficiency. Normal levels of serum B...
Oct 20, 2009
CEDAR KNOLLS, N.J., Oct 20, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB:EMIS) today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere's proprietary Eligen(R) Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC...
Oct 15, 2009
CEDAR KNOLLS, N.J., Oct 15, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTCBB: EMIS) announced study results in which twice-daily oral salmon calcitonin using Emisphere's proprietary Eligen(R) Drug Delivery Technology significantly suppressed markers of cartilage and bone degradation versus placebo in men and ...
Oct 8, 2009
CEDAR KNOLLS, N.J., Oct 08, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced that the Company is introducing and launching its first commercially available product, oral Eligen(R) B12 (100 mcg). Oral Eligen(R) B12 (100 mcg) has been specifically developed to help improve Vitamin B12...
Sep 8, 2009
CEDAR KNOLLS, N.J., Sep 08, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced the publication of an article in the September issue of Clinical Pharmacology and Therapeutics, that describes previously reported findings of an independent clinical study designed to assess the pharmacoki...
Sep 1, 2009
CEDAR KNOLLS, N.J., Sep 01, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen(R) Technology, today announced that President and Chief Executive Officer, Michael ...
Aug 21, 2009
CEDAR KNOLLS, N.J., Aug 21, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced the completion of its previously announced sale of 5,714,286 shares of its common stock and warrants to purchase up to 2,685,714 additional shares of common stock in a registered direct offering with two institutio...
Aug 19, 2009
CEDAR KNOLLS, N.J., Aug 19, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced that it has received commitments from two institutional investors to purchase $4 million of securities in a registered direct offering. Emisphere entered into a securities purchase agreement with these investors pu...
Aug 11, 2009
CEDAR KNOLLS, N.J., Aug 11, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced financial and operational results for the second quarter and six months ended June 30, 2009. SECOND QUARTER FINANCIAL RESULTSFor the three months ended June 30, 2009, Emisphere reported a net loss of $3.7 million,...
Aug 7, 2009
CEDAR KNOLLS, N.J., Aug 07, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the second quarter ended June 30, 2009 on Tuesday, August 11, 2009 at 10:00 AM EDT. A press release will ...
Jul 28, 2009
CEDAR KNOLLS, N.J., Jul 28, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) announced today that, concurrent with the publication of two papers in the July/August issue of the peer reviewed journal, International Journal of Toxicology, which describes the toxicology of its Sodium N-[8-(2-hydroxybenzoyl) ...
Jun 22, 2009
CEDAR KNOLLS, N.J., Jun 22, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS.OB) and Syracuse University have entered into a research agreement to combine Emisphere's proprietary Eligen(R) oral drug delivery technology with a new oral drug delivery system developed in the laboratory of Robert Doyle, ...
Jun 8, 2009
CEDAR KNOLLS, N.J., Jun 08, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (NASDAQ: EMIS) today announced that it received notification from the NASDAQ Stock Market that its shares will be delisted from the NASDAQ Capital Market effective with the open of business on Tuesday, June 9, 2009. The delisting follows...
Jun 1, 2009
CEDAR KNOLLS, N.J., Jun 01, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (NASDAQ: EMIS) announced today that Novartis Pharma AG and Nordic Bioscience have completed recruitment for the planned second multi-center Phase III study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisp...
May 26, 2009
CEDAR KNOLLS, N.J., May 26, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (NASDAQ: EMIS) today announced data from a clinical study designed to assess the effect of oral administration of two peptides, GLP-1 and PYY3-36, utilizing Emisphere's Eligen(R) Technology on appetite suppression. The study was conducted at the...
May 21, 2009
CEDAR KNOLLS, N.J., May 21, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (NASDAQ: EMIS) today announced that it has received a $500,000 milestone payment from MannKind Corporation in connection with MannKind's recent filing and the U.S. Food & Drug Administration's (FDA's) acceptance of MannKind's New Drug Applicatio...
May 19, 2009
CEDAR KNOLLS, N.J., May 19, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (NASDAQ: EMIS) today announced that Franklin M. Berger, CFA, has been appointed to its Board of Directors, effective immediately. Mr. Berger's appointment fills the vacancy created by the recent resignation of Dr. Stephen K. Carter. Commenting ...
May 7, 2009
CEDAR KNOLLS, N.J., May 07, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (NASDAQ: EMIS) today announced its financial results for the three months ended March 31, 2009. Emisphere will host a conference call to discuss first quarter financial results at 10:00 AM EDT Thursday, May 7, 2009. The live webcast of the conf...
May 1, 2009
CEDAR KNOLLS, N.J., May 01, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (NASDAQ: EMIS) today announced that the company has been informed by an independent expert panel of scientists that its Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate ("SNAC") carrier has been provisionally designated as Generally Recognized as...
Apr 30, 2009
CEDAR KNOLLS, N.J., Apr 30, 2009 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) will host a conference call discussing its financial results for the first quarter ended March 31, 2009 on Thursday, May 7, 2009 at 10:00 AM EDT. The live webcast of the conference call can be accessed through the company's web...
Apr 13, 2009
CEDAR KNOLLS, N.J., Apr 13, 2009 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen(r) Technology, today announced that President and Chief Executive Officer, Michael V...
Apr 6, 2009
CEDAR KNOLLS, N.J. and WILMINGTON, N.C., Apr 6, 2009 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and nutritional supplements using its Eligen(r) Technology, and AAIPharma, Inc. announce a strategic alliance ...
Mar 16, 2009
CEDAR KNOLLS, N.J., Mar 16, 2009 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen(r) Technology, today announced that its financial statements for the fiscal year ended December 31, 2008, included...
Mar 10, 2009
CEDAR KNOLLS, N.J., Mar 10, 2009 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) today announced its financial results for the fourth quarter and year ended December 31, 2008. Emisphere will host a conference call to discuss fourth quarter and year end results at 10:00 AM EDT Tuesday, March 10, 2009. The li...
Mar 6, 2009
CEDAR KNOLLS, N.J., Mar 6, 2009 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) will host a conference call discussing its financial results for the fourth quarter and year ended December 31, 2008 on Tuesday, March 10, 2009 at 10:00 a.m. EDT. The live webcast of the conference call can be accessed through t...
Feb 20, 2009
CEDAR KNOLLS, N.J., Feb 20, 2009 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) announced results of a study indicating that orally administered salmon calcitonin using Emisphere's carrier, (5-CNAC) an Eligen(r) oral delivery technology, is effective in reducing bone breakdown. The study was conducted on behal...
Feb 3, 2009
CEDAR KNOLLS, N.J., Feb 3, 2009 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen(r) Technology, today announced that President and Chief Executive Officer, Michael V. Novinski, will present at th...
Dec 23, 2008
CEDAR KNOLLS, N.J., Dec 23, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) today announced that Kenneth I. Moch has been appointed to its Board of Directors. Mr. Moch will also serve on the Emisphere Audit Committee. He will fill the vacancy created by the death of Howard M. Pack, with a term that will co...
Dec 15, 2008
CEDAR KNOLLS, N.J., Dec 15, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS), regrets to report the death of Howard M. Pack. Mr. Pack served as a member of the Board of Directors of the Company since its inception in 1986, as well as serving as Executive Vice President of Finance from 1986 until his retirem...
Dec 8, 2008
CEDAR KNOLLS, N.J., Dec 8, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS), a biopharmaceutical company that focuses on an improved delivery of therapeutic molecules using its Eligen(r) Technology, announced plans to strengthen its financial foundation, bolster its long-term prospects, and maintain its foc...
Dec 1, 2008
CEDAR KNOLLS, N.J., Dec 1, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen(r) Technology, today announced that Michael V. Novinski, President and Chief Executive Officer, will present on De...
Nov 26, 2008
CEDAR KNOLLS, N.J., Nov 26, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) previously announced that on October 21, 2008 it received a letter from the NASDAQ Stock Market advising that, for the 10 consecutive trading days prior to October 21, 2008, the Company's market value of listed securities had been ...
Nov 24, 2008
CEDAR KNOLLS, N.J., Nov 24, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) announced today the results of a study by Novartis Pharma AG which demonstrates the achievement of a suitable PK profile of a new oral formulation of Parathyroid Hormone ("PTH") using Emisphere's Eligen(r) Technology. This initial ...
Nov 6, 2008
CEDAR KNOLLS, N.J., Nov 6, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) today announced its financial results for the third quarter ended September 30, 2008. Emisphere will host a conference call to discuss third quarter results at 10:00 AM EST Thursday, November 6, 2008. A live Webcast of the confer...
Nov 6, 2008
CEDAR KNOLLS, N.J., Nov 6, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen® Technology, today announced that President and Chief Executive Officer Mich...
Nov 4, 2008
CEDAR KNOLLS, N.J., Nov 4, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) will host a conference call discussing its financial results for the third quarter 2008 on Thursday, November 6, 2008 at 10:00 AM EST.The live webcast of the conference call can be accessed through the company's web site...
Oct 27, 2008
CEDAR KNOLLS, N.J., Oct 27, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) announced that on October 21, 2008 it received a letter from the NASDAQ Stock Market (the "NASDAQ Letter") advising that, for the last 10 consecutive trading days, the Company's market value of listed securities had been below t...
Oct 21, 2008
CEDAR KNOLLS, N.J., Oct 21, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) announced today that Novartis Pharma AG and Nordic Bioscience have initiated a second multi-center Phase III study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere's proprietary Elige...
Oct 14, 2008
CEDAR KNOLLS, N.J., Oct 14, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) announced today that a study by Novartis Pharma AG and its partner Nordic Bioscience demonstrated that oral salmon calcitonin using Emisphere's proprietary Eligen® Technology taken 30 to 60 ...
Oct 1, 2008
CEDAR KNOLLS, N.J., Oct 1, 2008 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) today announced the publication of a study assessing the oral delivery of GLP-1 and PYY3-36 using Emisphere's proprietary delivery technology. The study showed, for the first time, that satiety peptides such as GLP-1 and PYY3-36 ...
Sep 22, 2008
CEDAR KNOLLS, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that Novartis Pharma AG and Nordic Bioscience have completed recruitment for a multi-center Phase III study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere's proprietary Eligen Technolo...
Aug 19, 2008
CEDAR KNOLLS, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) has announced that Nicholas J. Hart has joined the company as Vice President of Strategy and Development. In this capacity, Mr. Hart will be responsible for the planning and commercial development aspects of the company's Eligen...
Aug 11, 2008
CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced its financial results for the second quarter ended June 30, 2008. Emisphere will host a conference call to discuss second quarter results at 10:00 AM EDT Monday, August 11, 2008. A live Webcast...
Aug 7, 2008
CEDAR KNOLLS, N.J., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will host a conference call to discuss second quarter results at 10:00 AM EDT Monday, August 11, 2008. A live Webcast of the conference call can be accessed through the company's website at: www.emisphere.com. The li...
Aug 5, 2008
CEDAR KNOLLS, N.J., Aug 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that Novartis Pharma AG has finished recruitment for a multi-center Phase III study exploring the safety and efficacy of Salmon Calcitonin and Emisphere's proprietary Eligen®...
Jul 28, 2008
CEDAR KNOLLS, N.J., July 28 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced new human clinical data demonstrating a new, more bioavailable oral form Vitamin B12 and a potential new avenue for addressing the problems with B12 supplementation. As demonstrated by the data, the Eligen®...
Jul 8, 2008
CEDAR KNOLLS, N.J., July 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced findings from a clinical study assessing the oral delivery of GLP-1 peptide safely and effectively. The study used a delivery-agent-based approach using Emisphere's Eligen®...
Jun 30, 2008
CEDAR KNOLLS, N.J., June 30 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that Novartis Pharma AG has launched a Phase I study in postmenopausal women to determine the safety and tolerability of oral PTH134, a combination of human PTH-1-34 and the absorption enhancer 5-CNAC using Emisphere's proprietary E...
Jun 23, 2008
CEDAR KNOLLS, N.J., June 23 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) and Novo Nordisk A/S (NYSE: NVO) have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists, which have the potential of treating Type 2 diab...
May 16, 2008
CEDAR KNOLLS, N.J., May 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Highlighting the company's expectations for the future as well as its current product pipeline, Michael V. Novinski, President and CEO of Emisphere Technologies, Inc. (Nasdaq: EMIS), was featured in an extensive interview published recently in The Wall Street ...
May 7, 2008
CEDAR KNOLLS, N.J., May 7 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced its financial results for the first quarter ended March 31, 2008. Emisphere will host a conference call to discuss first quarter results at 10:00 AM EDT Wednesday, May 7, 2008. A live Webcast of the conference call can be ...
May 2, 2008
CEDAR KNOLLS, N.J., May 2, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will host a conference call discussing its financial results for the first quarter ended March 31, 2008 on Wednesday, May 7, 2008 at 10:00 AM EDT. A live webcast of the conference call can be accessed through t...
Apr 28, 2008
CEDAR KNOLLS, N.J., April 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced that on April 22, 2008 it received a letter from the NASDAQ Stock Market (the "NASDAQ Letter") advising that, for the last 10 consecutive trading days, the Company's market value of listed securities had ...
Apr 16, 2008
CEDAR KNOLLS, N.J., April 16 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that additional preclinical in vivo studies using dogs further demonstrate that its proprietary eligen® technology enhances the absorption of oral B12. These data confirm in a second species E...
Apr 15, 2008
CEDAR KNOLLS, N.J., April 15 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), announced today that it will host its Annual Stockholders Meeting on Thursday, May 8, 2008, at the Westin Governor Morris, located at Two Whippany Road, Morristown, New Jersey. The meeting will begin at 10:00 a.m. EDT. ABOUT EMISPHERE...
Mar 19, 2008
CEDAR KNOLLS, N.J., March 19 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) released today results of additional animal studies demonstrating that its proprietary eligen® technology enhances the absorption of oral B12 at considerably lower doses than were used previously. The lower do...
Mar 17, 2008
CEDAR KNOLLS, N.J., March 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced its financial results for the fourth quarter and year ended December 31, 2007. Emisphere will host a conference call to discuss fourth quarter results at 10:00 AM EDT Wednesday, March 19, 200...
Mar 14, 2008
CEDAR KNOLLS, N.J., March 14 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will host a conference call discussing its financial results for the fourth quarter and year ended December 31, 2007 on Wednesday, March 19, at 10:00 AM EDT. The live webcast of the conference call can be accessed through the company's...
Feb 11, 2008
CEDAR KNOLLS, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its eligen® technology, today announced that it will Web cast its presentation at the BIO CEO & Inv...
Feb 7, 2008
CEDAR KNOLLS, N.J., Feb 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that recent animal studies have demonstrated proof of concept that absorption of oral vitamin B12 using the company's proprietary eligen® technology was 15-30 times g...
Feb 4, 2008
NEW YORK, Feb. 4 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its eligen® technology, today announced that the company will present at the BIO CEO & Investor Conference on ...
Jan 31, 2008
CEDAR KNOLLS, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), announced today that it will host a teleconference on Thursday, February 7, at 10:00 AM EST. President and Chief Executive Officer Michael V. Novinski will discuss the company's emerging business strategy. Emisphere is a biopharmaceutical company...
Dec 6, 2007
CEDAR KNOLLS, N.J., Dec. 6 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has retained Adam Friedman Associates, LLC (AFA) as its agency of record for Investor Relations. Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceuti...
Nov 6, 2007
TARRYTOWN, N.Y., Nov. 6 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced its financial results for the third quarter ended September 30, 2007. Emisphere Technologies, Inc. will host a conference call to discuss third quarter results at 10:00 AM EST today. A live Webcast of the conference call ca...
Oct 31, 2007
TARRYTOWN, N.Y., Oct. 31 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it will move its corporate headquarters from Tarrytown, New York to Cedar Knolls, New Jersey. Emisphere will retain its scientific staff and laboratory facilities in Tarrytown. Emisphere Technologies, Inc. is a biopharmaceutical comp...
Oct 24, 2007
TARRYTOWN, N.Y., Oct. 24 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Gary Riley has been appointed to the position of Vice President, Nonclinical Development and Applied Biology, effective November 6, 2007. Dr. Riley will be responsible for the oversight and management of nonclinical drug efficacy...
Sep 25, 2007
TARRYTOWN, N.Y., Sept. 25 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) has agreed to accept $18 million from Eli Lilly and Company (NYSE: LLY) to settle the pending litigation between the two companies. The parties will promptly submit a Stipulation of Dismissal with Prejudice of their litigation to the Unit...
Aug 29, 2007
TARRYTOWN, N.Y., Aug. 29 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Michael R. Garone has been appointed to the position of Chief Financial Officer (CFO). Mr. Garone previously held the role of CFO and Interim Chief Executive Officer of Astralis, Ltd., a biotechnology company. Mr. Garone will re...
Aug 22, 2007
TARRYTOWN, N.Y., Aug. 22 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Paul Lubetkin has been appointed to the position of Vice President and General Counsel, effective September 4, 2007. Mr. Lubetkin will be responsible for the overall planning, management and execution of the legal function, includ...
Aug 17, 2007
TARRYTOWN, N.Y., Aug 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has entered into agreements to sell 2.0 million shares of common stock and warrants to purchase 0.4 million shares of common stock, at a purchase price of $3.785 per unit. The five-year warrants...
Aug 7, 2007
TARRYTOWN, N.Y., Aug 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced its financial results for the second quarter ended June 30, 2007. "Emisphere's product pipeline is growing increasingly robust," said Michael V. Novinski, President/Chief Executive Officer of Emis...
Aug 3, 2007
TARRYTOWN, N.Y., Aug. 3 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will Webcast its quarterly earnings conference call on Tuesday, August 7, 2007, at 10:00 AM EDT to discuss the results of its second quarter ended June 30, 2007. All interested parties are invited to listen to Emisphere's President/Chief Ex...
Jun 12, 2007
TARRYTOWN, N.Y., June 12 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Laura Kragie, M.D., has been appointed to the position of Vice President of Clinical Development and Chief Medical Officer, effective immediately. Dr. Kragie is the previous President and Chief Scientific Officer of Kragie BioMed...
May 24, 2007
TARRYTOWN, N.Y., May 24 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. ("Emisphere") (Nasdaq: EMIS) has been notified that Novartis Pharma AG and its development partner Nordic Bioscience have initiated the Phase III clinical program of oral calcitonin (referred to as SMC021) for the treatment of osteoarthritis, a chronic, irreversible ...
May 4, 2007
TARRYTOWN, N.Y., May 4, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced its financial results for the first quarter ended March 31, 2007. The Company also provided an update on product and corporate developments that occurred during the first quarter. First Quarter Financial ...
May 2, 2007
TARRYTOWN, N.Y., May 2 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a teleconference to discuss its 2007 first quarter financial results on Friday, May 4, 2007, beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific). A replay of the call will be accessible approximately two hours following the end of the cal...
Apr 18, 2007
TARRYTOWN, N.Y., April 18 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it will host its Annual Stockholders Meeting on Friday, April 20, 2007 at the Westchester Marriott Hotel, 670 White Plains Road, Tarrytown, NY. The meeting will begin at 10:00 a.m. EDT. Webcast Information ...
Apr 10, 2007
TARRYTOWN, N.Y., April 10 /PRNewswire-FirstCall/ -- The Board of Directors of Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it has appointed Michael V. Novinski to the position of President and Chief Executive Officer effective immediately. Previously, Mr. Novinski was President of Organon USA Inc., a business unit of Organo...
Mar 29, 2007
TARRYTOWN, N.Y., March 29 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) reported today results of two clinical studies conducted in collaboration with Professor Christoph Beglinger, M.D. Division of Gastroenterology and Hepatology, University Hospital Basel in Basel, Switzerland. The objective of the study with glucagon...
Mar 20, 2007
TARRYTOWN, N.Y., March 20 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today the formation of a Scientific Advisory Board ("SAB") to provide guidance for the Company's clinical development program for its oral insulin product. The SAB, which is chaired by Daniel J. Drucker, M.D., FRCPC, Professor of Medicine, ...
Mar 12, 2007
TARRYTOWN, N.Y., March 12 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. ("Emisphere," Nasdaq: EMIS) announced today an addendum to its fourth quarter and year ended 2006 financial results, reported on February 27, 2007. On March 5, 2007, the Company filed its annual report on Form 10-K for the year 2006. Such annual report on Form 10...
Feb 27, 2007
TARRYTOWN, N.Y., Feb. 27 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. ("Emisphere") (Nasdaq: EMIS) announced today that Novartis Pharma AG and its development partner Nordic Bioscience have notified Emisphere of the initiation of a Phase III clinical trial for the treatment of osteoporosis with an oral form of salmon calcitonin (refer...
Feb 27, 2007
TARRYTOWN, N.Y., Feb. 27 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the fourth quarter and year ended December 31, 2006. The Company also reviewed highlights from the year, including key developments in its proprietary product pipeline and an update on Emisphere's partnerships....
Feb 22, 2007
TARRYTOWN, N.Y., Feb. 22 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a teleconference to discuss its fourth quarter and year ended December 31, 2006 financial results on February 27, 2007, beginning at 10:00 a.m. Eastern Time. A replay of the call will be accessible approximately two hours following the end o...
Feb 8, 2007
TARRYTOWN, N.Y., Feb 08, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will present at the BIO CEO & Investor Conference, taking place on February 12-14, 2007 at the Waldorf- Astoria Hotel in New York City. Lewis H. Bender, President and Chief Executive Officer, w...
Jan 28, 2007
TARRYTOWN, N.Y., Nov 28, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will present at the Lazard Capital Markets Third Annual Life Sciences Conference, taking place on November 28-29, 2006 at The New York Palace Hotel in New York City. Michael M. Goldberg, M.D., Ch...
Jan 16, 2007
TARRYTOWN, N.Y., Jan. 16 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. ("Emisphere", Nasdaq: EMIS) today announced that Michael M. Goldberg, M.D. Emisphere's Chief Executive Officer, Chairman of the Board, and member of the board, has been terminated as Chief Executive Officer and Chairman of the Board, effective January 16, 2007. Emi...
Nov 9, 2006
TARRYTOWN, N.Y., Nov. 9 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the third quarter ended September 30, 2006. Third Quarter Financial Results Emisphere reported an operating loss of $8.7 million for the quarter ended September 30, 2006, compared to an opera...
Nov 8, 2006
Patients Across Three Dose Groups of Oral Insulin with Stable Hemoglobin A1c (HbA1c) Levels at Baseline Experienced Mean Decrease in HbA1c Highest Dose of Oral Insulin Shown To Be Statistically Significant Versus Placebo in Decrease of HbA1c in Patients with Baseline of 8.0% and Above Webca...
Nov 6, 2006
TARRYTOWN, N.Y., Nov. 6 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a teleconference to discuss its third quarter 2006 financial results on Thursday, November 9, 2006, beginning at 10:00 a.m. Eastern Time. A replay of the call will be accessible approximately two hours following the end of the call and will b...
Nov 3, 2006
TARRYTOWN, N.Y., Nov. 3 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will present at the Rodman & Renshaw 8th Annual Healthcare Conference, taking place on November 6-8, 2006 at the New York Palace Hotel in New York City. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will p...
Oct 30, 2006
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Oct. 30, 2006-- Emisphere Technologies, Inc. ("Emisphere", NASDAQ: EMIS) announced today results from its 90-day, Phase 2 study of its oral insulin product utilizing its eligen® oral delivery technology. The four-arm study evaluated the safety and efficacy of low and high f...
Oct 17, 2006
TARRYTOWN, N.Y., Oct. 17 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will participate in the 2006 Bio Investor Forum, showcasing the leading growth companies in life sciences, taking place October 17-19, 2006 at The Palace Hotel in San Francisco. Michael M. Goldberg, M.D., Chairman and Chief Exe...
Sep 25, 2006
TARRYTOWN, N.Y., Sept. 25 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will participate in the UBS 2006 Global Life Sciences Conference, being held at the Grand Hyatt in New York City. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present on Tuesday, September 26, 2006, at...
Sep 20, 2006
TARRYTOWN, N.Y., Sept. 20 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will participate in the 2nd Annual Oppenheimer Diabetes Conference, being held at the Madison Towers, Jolly Hotel in New York City. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present on Thursday, Sep...
Sep 12, 2006
TARRYTOWN, N.Y., Sept. 12 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will participate in the ThinkEquity Partners LLC 4th Annual Growth Conference, being held at The Ritz-Carlton in San Francisco. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present on Wednesday, Septem...
Sep 5, 2006
TARRYTOWN, N.Y., Sept. 5 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. ("Emisphere") (Nasdaq: EMIS) announced today that Novartis Pharma AG has notified Emisphere of new Phase I data indicating that recombinant human growth hormone (rhGH) can be absorbed when given to growth hormone-deficient (GHD) patients in a prototype oral formulat...
Aug 8, 2006
TARRYTOWN, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the second quarter ended June 30, 2006. The Company also reviewed highlights of the quarter, including continued progress in advancing its heparin and insulin development programs, a new multi-product research coll...
Aug 1, 2006
TARRYTOWN, N.Y., Aug. 1 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a teleconference to discuss its second quarter 2006 financial results on Tuesday, August 8, 2006, beginning at 10:00 a.m. Eastern Time. A replay of the call will be accessible approximately three hours following the end of the call and will b...
Jul 18, 2006
TARRYTOWN, N.Y., July 18 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has entered into a multi-product research collaboration agreement with Roche to explore the use of Emisphere's eligen® technology in feasibility studies for new oral formulations of a numbe...
Jun 19, 2006
TARRYTOWN, N.Y.--(BUSINESS WIRE)--June 19, 2006--Emisphere Technologies, Inc. ("Emisphere", Nasdaq: EMIS) announced today that it is scheduled to join the Russell 3000 Index when Russell Investment group reconstitutes its family of U.S. indexes on June 30, according to a preliminary list of additions posted on Friday, June 16th on www.russell....
May 25, 2006
TARRYTOWN, N.Y., May 25 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. ("Emisphere", Nasdaq: EMIS) announced today that Novartis Pharma AG has notified Emisphere that Novartis Pharma AG has completed the planned preclinical safety studies for the oral calcitonin product using Emisphere's eligen® del...
May 23, 2006
TARRYTOWN, N.Y., May 23, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will host its Annual Shareholders Meeting on Thursday, May 25, 2006 at the Westchester Marriott Hotel, 670 White Plains Road, Tarrytown, NY, beginning at 10:00 a.m., Eastern Daylight Time. Webcast Information ...
May 16, 2006
TARRYTOWN, N.Y., May 16 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has completed the sale of 4 million shares of common stock at $8.26 per share, the closing bid price of the Company's common stock on May 9, 2006, pursuant to Emisphere's previously filed shelf registration statement, which was ...
May 10, 2006
TARRYTOWN, N.Y., May 10 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has entered into agreements to sell 4 million shares of common stock at $8.26 per share, the closing bid price on May 9, 2006, pursuant to Emisphere's previously filed shelf registration statement, which was declared effective b...
May 5, 2006
TARRYTOWN, N.Y., May 5 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced preliminary financial results for the first quarter ended March 31, 2006. The Company also reviewed highlights of the quarter, including continued progress in advancing its heparin and insulin development programs, receipt of milestone p...
May 1, 2006
TARRYTOWN, N.Y., May 1 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. ("Emisphere", Nasdaq: EMIS) announced today that Novartis Pharma AG has notified Emisphere that Novartis Pharma AG will initiate the development of an oral human growth hormone (rhGH) product using Emisphere's eligen® delivery tec...
May 1, 2006
TARRYTOWN, N.Y., May 1 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a teleconference to discuss its 2006 first quarter financial results on Friday, May 5, 2006, beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific). A replay of the call will be accessible approximately two hours following the end of the cal...
Apr 26, 2006
TARRYTOWN, N.Y., April 26 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that the United States Federal District Court in Indianapolis has granted Emisphere's application and ordered Eli Lilly and Company to assign to Emisphere the patent application filed by Lilly in February 2002 for a patent on the use ...
Apr 12, 2006
TARRYTOWN, NY, April 12 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that the U.S. Patent and Trademark Office has granted an additional patent to Emisphere regarding the pulmonary delivery of proteins, using Emisphere's eligen® technology. Emisphere received U.S. P...
Apr 11, 2006
TARRYTOWN, N.Y., April 11 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it has completed enrollment of the first 120 patients in its Phase II oral insulin clinical trial (the "Trial"), and has received permission from regulatory authorities in India to expand the Trial enrollment from 120 patients to 140 ...
Apr 7, 2006
TARRYTOWN, N.Y., April 7, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), announced today that on April 4, 2006, the Company's Board of Directors appointed John D. Harkey, Jr. to the Board of Directors, effective April 10, 2006. Mr. Harkey is the Chairman and Chief Executive Office...
Mar 31, 2006
TARRYTOWN, N.Y., March 31 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results of a clinical study designed to compare heparin administered in the Company's proprietary oral formulation to heparin administered by the two standard methods of injection. The purpose of the study was to demonstrate that hepa...
Mar 23, 2006
BERKELEY HEIGHTS, N.J. and TARRYTOWN, N.Y., March 23 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) and Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that they have entered into an exclusive worldwide licensing agreement to develop an oral formulation of a gallium-containing compound. Gallium compounds are bone-targe...
Mar 14, 2006
TARRYTOWN, N.Y., March 14 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the fourth quarter and year ended December 31, 2005. The Company also reviewed highlights of the year, including progress in advancing its product portfolio and a successful result in a contract dispute lawsuit a...
Mar 9, 2006
TARRYTOWN, N.Y., March 9 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a teleconference to discuss its 2005 fourth quarter and year end financial results on Tuesday, March 14, 2006, beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific). A replay of the call will be accessible approximately two hours followin...
Mar 8, 2006
TARRYTOWN, N.Y., March 8 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) ("Emisphere") announced today that Novartis has executed its license option for the development and commercialization of an oral parathyroid hormone (PTH) using Emisphere's eligen® delivery technology. Emisphere i...
Mar 1, 2006
TARRYTOWN, N.Y., March 1, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that it will participate in the SG Cowen & Co. 26th Annual Health Care Conference, being held at The Marriott Copley Place in Boston. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer...
Feb 15, 2006
TARRYTOWN, N.Y., Feb. 15 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has achieved a second milestone under its November 2004 agreement with Roche to develop new oral formulations of a Roche small molecule compound for the treatment of bone-related diseases. The achievement of this milestone, res...
Feb 13, 2006
TARRYTOWN, N.Y., Feb. 13 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that it will participate in the BIO CEO & Investor Conference, being held at The Waldorf Astoria Hotel in New York City. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present on Wednesday, February 15, 2006...
Feb 7, 2006
TARRYTOWN, N.Y., Feb. 7 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today the Company filed papers in response to a recent motion by Eli Lilly & Co. (NYSE: LLY) (Lilly), seeking to modify the U.S. Federal District Court of the Southern District of Indiana's January 6th ruling in favor of Emisphere. Lilly...
Jan 17, 2006
TARRYTOWN, N.Y., Jan. 17 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), announced today that its stockholders approved all proposals at its special meeting of stockholders. At the special meeting held today, the Emisphere stockholders approved the exchange of the seven-year 11% senior secured loan issued by Em...
Jan 10, 2006
TARRYTOWN, N.Y., Jan. 10 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that it will participate in the 24th JPMorgan Annual Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, CA. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present on Thursday, Ja...
Jan 9, 2006
TARRYTOWN, N.Y., Jan. 9 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that U.S. Federal District Court Judge David F. Hamilton of the Southern District of Indiana, has determined that Eli Lilly & Co. (NYSE: LLY), ("Lilly") has breached its contractual obligations and that the Lilly license and collabo...
Jan 5, 2006
TARRYTOWN, N.Y., Jan. 5 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it has received notice from the United States District Court for the Southern District of Indiana that United States District Judge David F. Hamilton intends to release, after the close of trading on Friday, January 6, 2006, a decision ...
Dec 13, 2005
TARRYTOWN, N.Y., Dec 13, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- In accordance with NASDAQ Marketplace Rule 4803(a), Emisphere Technologies, Inc. (Nasdaq: EMIS) is required to issue this press release announcing that on December 9, 2005 it received a Staff Deficiency Letter from the NASDAQ indicating that the Company was not i...
Dec 12, 2005
TARRYTOWN, N.Y., Dec. 12 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that positive clinical data generated by Drs. Daniel Manicourt and Jean-Pierre Devogelaer from the Department of Rheumatology at the University Hospital St-Luc, Universite Catholique de Louvain, Brussels, Belgium evaluating oral salmon...
Nov 10, 2005
TARRYTOWN, N.Y., Nov. 10 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today provided a description of clinical development progress and selected financial information for the third quarter ended September 30, 2005. As of September 30, 2005, Emisphere held cash, cash equivalents, restricted cash and investmen...
Nov 7, 2005
TARRYTOWN, N.Y., Nov. 7 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it has received written guidance from the U.S. Food and Drug Administration (the "FDA") regarding the Company's planned Phase III trial with oral heparin. The planned trial is designed to determine the safety and efficacy of oral ...
Nov 3, 2005
TARRYTOWN, N.Y., Nov. 3 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it has received permission from regulatory authorities in India to commence a Phase II trial for its oral insulin product. Emisphere intends to initiate patient enrollment later this month for a 90-day, multi-center, do...
Nov 3, 2005
TARRYTOWN, N.Y., Nov. 3 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that it will participate in the Rodman & Renshaw Techvest 7th Annual Healthcare Conference, being held at The Palace Hotel in New York, NY. Michael M. Goldberg, Chairman and Chief Executive Officer, will present on Monday, November...
Nov 1, 2005
TARRYTOWN, N.Y., Nov. 1 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's financial results for the quarter ended September 30, 2005. The call will be held on Thursday, November 10, 2005, beginning at 10:30 a.m. Eastern Standard Time (7:30 a.m. Pacific). A replay of the ca...
Oct 21, 2005
TARRYTOWN, N.Y., Oct. 21 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that it will participate in the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference, being held at The Palace Hotel in New York, NY. Lewis H. Bender, Senior Vice President, Business Development, will present on Tuesday, Oc...
Oct 17, 2005
TARRYTOWN, N.Y., Oct. 17 /PRNewswire-FirstCall/ -- In accordance with NASDAQ Marketplace Rule 4803(a), Emisphere Technologies, Inc. (Nasdaq: EMIS) is required to issue this press release announcing that on October 12, 2005 it received a Staff Deficiency Letter from the NASDAQ indicating that the Company was not in compliance with NASDAQ's audit...
Sep 26, 2005
TARRYTOWN, N.Y., Sept. 26 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has raised $15 million through a senior secured term loan financing with funds managed by MHR Fund Management LLC. Emisphere plans to use the proceeds of the loan to fund its clinical development programs in oral heparin and ...
Sep 19, 2005
TARRYTOWN, N.Y., Sept. 19 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that it will participate in the Merriman Curhan Ford & Co. 2nd Annual Investor Summit, being held at the Mark Hopkins InterContinental Hotel in San Francisco, CA. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, w...
Sep 19, 2005
TARRYTOWN, N.Y., Sept 19, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it has completed dosing all arms of a clinical trial to compare heparin delivered by intravenous and subcutaneous injection to Emisphere's oral heparin capsule formulation, which uses the eligen...
Sep 12, 2005
TARRYTOWN, N.Y., Sept. 12 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that it will participate in the ThinkEquity Partners 3rd Annual Growth Conference, being held at the Ritz Carlton Hotel in San Francisco, CA. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present on Wednesday,...
Sep 1, 2005
TARRYTOWN, N.Y., Sept. 1 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that it will participate in the Oppenheimer Diabetes Conference, being held at the Warwick Hotel in New York, NY. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present on Wednesday, September 7, 2005, at 2:05 p...
Aug 4, 2005
TARRYTOWN, N.Y., Aug. 4 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the second quarter ended June 30, 2005. Emisphere reported a net loss of $5.8 million, or $0.25 per share, for the quarter ended June 30, 2005, as compared to a net loss of $8.8 million, or $0.48 per share for th...
Jul 20, 2005
TARRYTOWN, N.Y., July 20 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's financial results for the quarter ended June 30, 2005. The call will be held on Thursday, August 4, 2005, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A replay of the call will be acces...
Jul 6, 2005
TARRYTOWN, N.Y., July 6, 2005 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that Winstanley Enterprises, LLC has completed its purchase of Emisphere's Connecticut facility previously used for pre-clinical, toxicology and analytical laboratory work. The purchase price was $4.2 million after a...
Jul 5, 2005
TARRYTOWN, N.Y., July 5 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has received the first milestone payment from Roche under the two companies' agreement to develop new oral formulations of a Roche small molecule compound for the treatment of bone-related diseases. The achievement of this mile...
May 16, 2005
TARRYTOWN, N.Y., May 16 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that its corporate presentation at the Bank of America Securities Health Care Conference will be webcast live over the internet. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present to investors on Wednesday, M...
May 13, 2005
TARRYTOWN, N.Y., May 13 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. will host its annual shareholders meeting on May 23, 2005 at the Doubletree Hotel, 455 South Broadway, Tarrytown, N.Y., beginning at 10:00 a.m., Eastern Daylight Time. ON-SITE ATTENDANCE INFORMATION: For those traveling from New York City, Emis...
May 10, 2005
TARRYTOWN, N.Y., May 10 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the first quarter ending March 31, 2005. The Company also reviewed highlights of the quarter, including progress in commercializing its proprietary eligen® drug delivery technology....
May 2, 2005
TARRYTOWN, N.Y., May 2 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's financial results for the quarter ended March 31, 2005. The call will be held on Tuesday, May 10, 2005, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A replay of the call will be accessibl...
Apr 4, 2005
TARRYTOWN, N.Y., April 4 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it has retired its remaining debt due to an affiliate of the Elan Corporation, plc (NYSE: ELN). The $13 million cash payment, plus issuance of a warrant to purchase 600,000 shares of the Company's common stock at $3.88 per share, ...
Apr 1, 2005
TARRYTOWN, N.Y., April 1 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today the closing of an offering of 4 million shares of common stock and warrants to purchase an additional 1.5 million shares of common stock in a placement under Emisphere's shelf registration statement. The shares of common stock and warr...
Mar 21, 2005
TARRYTOWN, N.Y., March 21 /PRNewswire-FirstCall/ -- In accordance with Nasdaq regulations, Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that its 2004 financial statements included in the Company's FORM 10-K previously filed on March 11, 2005 contained a going-concern uncertainty from its auditors. Today's announcement is meant to...
Feb 28, 2005
TARRYTOWN, N.Y., Feb 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (nasdaq: EMIS) today announced that Michael M. Goldberg, M.D., Chairman and CEO, will make a presentation at the Wells Fargo Healthcare Conference. The conference is being held at the St. Regis Hotel in New York, NY. The presentation is scheduled ...
Feb 25, 2005
TARRYTOWN, N.Y., Feb. 25 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Elliot M. Maza, J.D., C.P.A, Chief Financial Officer, will make a presentation at the Wall Street Analyst Forum. The conference is being held at the Roosevelt Hotel in New York, N.Y. The presentation is scheduled for Tuesday, Marc...
Feb 22, 2005
TARRYTOWN, N.Y., Feb 22, 2005 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will make a presentation at the BIO CEO & Investor Conference, being held at the Waldorf-Astoria in New York, NY. The presentation is schedul...
Feb 15, 2005
TARRYTOWN, N.Y., Feb 15, 2005 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the fourth quarter and year ended December 31, 2004. The Company also reviewed highlights of the year, including progress in commercializing its proprietary eligen® d...
Feb 4, 2005
TARRYTOWN, N.Y., Feb 04, 2005 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's financial results for the fourth quarter and year ended December 31, 2004. The call will be held on Tuesday, February 15, 2005, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pac...
Feb 1, 2005
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 1, 2005--Emisphere Technologies, Inc. (NADSAQ: EMIS) announced today that it has filed an amendment to the S-3 registration statement that was originally filed with the SEC on July 8, 2004. Today's filing is not an additional registration statement. A registration statement relating to these se...
Jan 31, 2005
TARRYTOWN, N.Y., Jan 31, 2005 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Elliot M. Maza, J.D., C.P.A., Chief Financial Officer, will make a presentation during the Brean Murray Institutional Investor Conference. The presentation is scheduled for Wednesday, February 2, 2005 at 7:30 a...
Dec 28, 2004
TARRYTOWN, N.Y., Dec. 28 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it has entered into an agreement to repay its outstanding note to Elan Corporation PLC (NYSE: ELN) in cash and stock. Under terms of the new agreement, Emisphere will pay Elan a total of $26 million cash and up to 1.2 millio...
Dec 28, 2004
TARRYTOWN, N.Y., Dec. 28 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it has entered into an agreement with Kingsbridge Capital Limited, whereby Kingsbridge has committed to purchase up to $20 million of Emisphere's common stock over a two-year period. Under the terms of the commitment, Emisph...
Dec 1, 2004
TARRYTOWN, N.Y., Dec. 1 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. ("Emisphere", Nasdaq: EMIS) announced today that it has received $10 million from Novartis Pharma AG in exchange for a convertible note. The investment is in conjunction with an option and license agreement between Novartis and Emisphere entered into today...
Nov 18, 2004
TARRYTOWN, N.Y., Nov. 18 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has entered into a licensing agreement with Roche to develop oral formulations of undisclosed small molecule compounds approved for use in the field of bone-related diseases. The agreement follows successful pre-clinical studie...
Nov 10, 2004
TARRYTOWN, N.Y., Nov. 10 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the presentation of new data utilizing its eligen® oral drug delivery technology at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Baltimore, Maryland, from November...
Nov 4, 2004
TARRYTOWN, N.Y., Nov. 4 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the third quarter ended September 30, 2004. The Company also reviewed highlights of the quarter including progress in commercializing its proprietary eligen® drug delivery technology....
Oct 25, 2004
TARRYTOWN, N.Y., Oct 25, 2004 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (NASDAQ:EMIS) will hold a conference call to discuss the Company's financial results for the third quarter ended September 30, 2004. The call will be held on Thursday, November 4, 2004, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A replay of the call...
Oct 25, 2004
TARRYTOWN, N.Y., Oct. 25 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that its corporate presentation at the Rodman and Renshaw Techvest 6th Annual Healthcare Conference will be webcast live over the internet. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer of Emisphere Technologies, wi...
Oct 11, 2004
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Oct. 11, 2004--Emisphere Technologies, Inc. (Nasdaq:EMIS), today announced that its corporate presentation at the BIO Emerging Company Investor Forum will be webcast live over the internet. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present to investors on Thursday, October 14, 2004,...
Sep 23, 2004
TARRYTOWN, N.Y., September 23 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has entered into a licensing agreement with Novartis Pharma AG (NYSE: NVS) to develop an oral formulation of recombinant human growth hormone (rhGH). The companies formed the agreement following successful compl...
Aug 4, 2004
TARRYTOWN, N.Y., Aug. 4 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it has selected a soft gelatin capsule formulation of unfractionated heparin (UFH), an antithrombotic/anticoagulant, that achieved clinically significant delivery of heparin. This formulation was chosen after the evaluation of res...
Aug 4, 2004
TARRYTOWN, N.Y., Aug. 4 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the second quarter ended June 30, 2004. The Company also highlighted its progress in development programs using its proprietary eligen® drug delivery technology. Emisphere re...
Jul 22, 2004
TARRYTOWN, N.Y.--(BUSINESS WIRE)--July 22, 2004--Emisphere Technologies, Inc. (Nasdaq:EMIS) will hold a conference call to discuss the Company's financial results for the second quarter ended June 30, 2004. The call will be held on Wednesday, August 4, 2004, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A replay of the call will be...
Jul 8, 2004
TARRYTOWN, N.Y., July 8 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission ("SEC"). When declared effective by the SEC, the registration statement will enable the Company to offer and sell up to five millio...
Jun 16, 2004
TARRYTOWN, N.Y., Jun 16, 2004 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has initiated a clinical trial in the United States as part of its oral heparin program, with the purpose of selecting an oral form of unfractionated heparin (UFH), an antithrombotic/anticoagulant, for use in...
Jun 7, 2004
TARRYTOWN, N.Y., June 7 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that results from a multiple-dose clinical study of an oral insulin tablet using its eligen® technology were presented as a poster at the 64th Scientific Sessions of the American Diabetes Associatio...
May 17, 2004
TARRYTOWN, N.Y., May 17 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that its corporate presentation at the Bank of America Securities Healthcare Conference will be webcast live over the internet. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present to investors on Wednesday, M...
May 6, 2004
TARRYTOWN, N.Y., May 6 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that its corporate presentation at the Rodman and Renshaw Techvest Annual Healthcare Conference will be webcast live over the internet. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present to investors on Wedne...
May 6, 2004
TARRYTOWN, N.Y., May 6 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the first quarter ending March 31, 2004. The Company also highlighted its progress related to development programs using its proprietary eligen® drug delivery technology. FIRS...
May 6, 2004
TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 6, 2004--Emisphere Technologies, Inc. will host its annual shareholders meeting on May 20, 2004 at Emisphere Technologies, Inc. headquarters (The Landmark at Eastview), 765 Old Saw Mill River Road, Tarrytown, NY, beginning at 10:00 a.m., Eastern Daylight Time. ONSITE ATTENDANCE INFORMATION: ...
Apr 27, 2004
TARRYTOWN, N.Y.--(BUSINESS WIRE)--April 27, 2004--Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's financial results for the first quarter ending March 31, 2004. The call will be held on Thursday, May 6, 2004, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A replay of the call will be acces...
Apr 20, 2004
TARRYTOWN, N.Y., Apr 20, 2004 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (Nasdaq:EMIS), a biopharmaceutical company pioneering the oral delivery of otherwise injectable or inhaled drugs, today announced that its corporate presentation at the White Mountain Capital Second Annual Biotechnology Conference will be webcast live over the int...
Feb 23, 2004
TARRYTOWN, N.Y., Feb. 23 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will be participating in two therapeutic focus sessions at the BIO CEO & Investor Conference. The three-day conference will be held at the Waldorf-Astoria in New York, NY, February 23-25, 2004. Michael M. Goldberg, M.D., Chairman and Chief Execu...
Feb 19, 2004
TARRYTOWN, N.Y., Feb. 19 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the fourth quarter and year ended December 31, 2003. The Company also highlighted its progress related to development programs using its proprietary eligen™ oral drug delivery technol...
Feb 6, 2004
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 6, 2004--Emisphere Technologies, Inc. (Nasdaq:EMIS) will hold a conference call to discuss the Company's financial results for the fourth quarter and year ended December 31, 2003. The call will be held on Thursday, February 19, 2004, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A replay of th...
Jan 29, 2004
TARRYTOWN, N.Y., Jan 29, 2004 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced preliminary results from the first multiple-dose clinical study of an oral insulin tablet using its eligen™ technology. The 13-patient study (seven treated; six control) evaluat...
Dec 11, 2003
TARRYTOWN, N.Y., Dec. 11 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that two new independent members, Stephen K. Carter, M.D., and Michael E. Black, have been appointed to its Board of Directors, and that Joseph R. Robinson, Ph.D., and Jere E. Goyan, Ph.D., have resigned their board positions and have ...
Dec 2, 2003
TARRYTOWN, N.Y., Dec. 2 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today the appointment of Elliot M. Maza, J.D., C.P.A., to the position of Chief Financial Officer. Mr. Maza will be responsible for providing leadership in the areas of financial operations, financial planning and analysis, investor relation...
Nov 12, 2003
TARRYTOWN, N.Y., Nov. 12 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the third quarter ended September 30, 2003. The Company also provided an update on development programs involving its proprietary eligen™ oral drug delivery technology. ...
Nov 10, 2003
TARRYTOWN, N.Y., Nov. 10 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that results from a clinical study evaluating an oral insulin tablet prototype (the EMISPHERE™ oral insulin tablet) were presented in a plenary session at the Diabetes Technology Society's 3rd Ann...
Oct 30, 2003
TARRYTOWN, N.Y., Oct 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's financial results for the third quarter ending September 30, 2003. The call will be held on Wednesday, November 12, 2003, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific)....
Oct 30, 2003
TARRYTOWN, N.Y. and SALT LAKE CITY, Oct. 30 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that six posters presenting the application of its unique eligen™ oral drug delivery technology were presented at the American Association of Pharmaceutical Scientists (AAPS) 20...
Oct 20, 2003
TARRYTOWN, N.Y., Oct 20, 2003 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), a biopharmaceutical company pioneering the oral delivery of otherwise injectable or inhaled drugs, today announced that its corporate presentation for the Techvest Fifth Annual Healthcare Conference and Expo will be webcast live ov...
Sep 22, 2003
TARRYTOWN, N.Y. and MINNEAPOLIS, Sept. 22 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that results of a Phase IIa study conducted by partner Novartis Pharma AG (NYSE: NVS) evaluating the performance of an oral tablet formulation of the peptide, salmon calcitonin ("calcitonin"), were presented at the 25t...
Sep 17, 2003
TARRYTOWN, N.Y., Sept. 17 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), a biopharmaceutical company pioneering the oral delivery of otherwise injectable or inhaled drugs, today announced that Robert A. Baughman, Pharm.D, Ph.D., Managing Director, Corporate Strategy, will make a presentation to investors and financial an...
Sep 16, 2003
TARRYTOWN, N.Y., Sep 16, 2003 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), a biopharmaceutical company pioneering the oral delivery of otherwise injectable or inhaled drugs, today announced the election of Arthur Dubroff to its board of directors, increasing the number of independent members to six and th...
Aug 12, 2003
INDIANAPOLIS, and TARRYTOWN, N.Y., Aug 12, 2003 /PRNewswire-FirstCall via COMTEX/ -- Eli Lilly and Company (NYSE: LLY) and Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that Lilly will continue to fund the development of only the oral parathyroid hormone 1-34 (PTH) program utilizing Emisphere's eligen™...
Aug 12, 2003
TARRYTOWN, N.Y., Aug 12, 2003 /PRNewswire-FirstCall via Comtex/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the second quarter ended June 30, 2003. The Company also provided an update on development programs involving its proprietary eligen™ oral drug delivery te...
Aug 4, 2003
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Aug. 4, 2003--Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's financial results for the second quarter ending June 30, 2003. The call will be held on Tuesday, August 12, 2003, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A replay of the call will be...
Jul 22, 2003
TARRYTOWN, N.Y., and GLASGOW, Scotland, July 22 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), a biopharmaceutical company pioneering the oral delivery of otherwise injectable or inhaled drugs, today announced the presentation of three posters at the 30th Annual Meeting & Exposition of the Controlled Release Society ...
Jun 20, 2003
TARRYTOWN, N.Y., June 20 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that an audio feed of its corporate presentation at the 2003 Biotechnology Industry Organization (BIO) Annual Convention's Business Forum (Partnering Forum and Investor Forum) will be webcast live over the Internet. Emisphere's presen...
Jun 19, 2003
TARRYTOWN, N.Y., Jun 19, 2003 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has signed a cooperative research and development agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the U.S. Department of Defense's lead laboratory for medical...
Jun 16, 2003
TARRYTOWN, N.Y., and NEW ORLEANS, June 16 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) along with its clinical collaborators, announced today promising results from two clinical studies evaluating an oral insulin prototype, both of which were presented at the 63rd Annual Scientific Sessions of the American Diabetes Asso...
Jun 11, 2003
TARRYTOWN, N.Y., Jun 11, 2003 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), a biopharmaceutical company pioneering the oral delivery of otherwise injectable or inhaled drugs, announced today that two separate oral insulin clinical studies in type 2 diabetic patients will be presented at the 63rd Annual Scie...
Jun 3, 2003
TARRYTOWN, N.Y.--(BUSINESS WIRE)--June 3, 2003--Emisphere Technologies, Inc. (Nasdaq:EMIS) will be presenting at the White Mountain Capital 2003 Biotechnology Conference on Thursday, June 5, 2003, at 4:15 p.m. EDT. The one-day conference will be held at the IBM Palisades Conference Center in Palisades, NY. For those unable to attend...
Jun 3, 2003
TARRYTOWN, N.Y., Jun 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. will be presenting at the UBS Warburg Global Specialty Pharmaceuticals Conference on Wednesday, June 4, 2003, at 2:30 p.m. EDT. The two-day conference will be held at the Grand Hyatt Hotel in New York, NY, June 4-5, 2003. For those unabl...
May 27, 2003
TARRYTOWN, N.Y., May 27 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. will be presenting at the Friedman Billings Ramsey 7th Annual Technology & Growth Investor Conference on Thursday, May 29, 2003, at 9:20 a.m. EDT. The two-day conference, which will be held at the Millennium Hotel Broadway in New York, New York, features more tha...
May 13, 2003
TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 13, 2003--Emisphere Technologies, Inc. (NASDAQ:EMIS) will host its annual shareholders meeting on May 15, 2003 at the Westchester Marriott Hotel in Tarrytown, NY, beginning at 10:00 a.m., Eastern Daylight Time. ONSITE ATTENDANCE INFORMATION: For those traveling from New York City, Emi...
May 8, 2003
TARRYTOWN, N.Y., May 8 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the first quarter ended March 31, 2003. The Company also provided an update on development programs involving its proprietary eligen™ oral drug delivery technology. ...
May 8, 2003
Tarrytown, NY, May 8, 2003 --- Emisphere Technologies, Inc. (NASDAQ: EMIS) announced today that it is initiating clinical testing of an oral insulin formulation in type 2 diabetic patients in the United States under an Investigational New Drug (IND) application filed with the United States Food and Drug Administration (FDA). The formulation use...
May 1, 2003
TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 1, 2003--Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's first quarter financial results for the quarter ending March 31, 2003. The call will be held on Thursday, May 8, 2003, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A replay of the call wil...
Mar 6, 2003
SALT LAKE CITY, Mar 6, 2003 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today presented data from a clinical study in patients with type II diabetes that evaluated a capsule preparation of insulin using its eligen™ oral drug delivery technology. The data was presented at...
Mar 5, 2003
TARRYTOWN, N.Y., Mar 5, 2003 /PRNewswire-FirstCall via COMTEX/ --Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced a delay related to a previously disclosed near-term milestone to secure a partnership for its oral insulin candidate. Emisphere held a conference call and webcast at 8:00 am Eastern time on March 5, 2003 to discuss the ba...
Mar 4, 2003
TARRYTOWN, N.Y., Mar 4, 2003 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) announced today that it will host a conference call and webcast at 8:00 a.m., Eastern Standard Time, on Wednesday, March 5, 2003 to discuss the status of an oral insulin partnership. To access the live call or the seven-day archive via the internet, ...
Feb 26, 2003
TARRYTOWN, N.Y., Feb 26, 2003 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced favorable results of a Phase IIa study with Novartis Pharma AG evaluating the performance in post-menopausal women of an oral tablet formulation of the peptide, salmon calcitonin ("calcitonin"), which is currently avail...
Feb 20, 2003
TARRYTOWN, N.Y., Feb 20, 2003 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that an audio feed of its corporate presentation at the Biotechnology Industry Organization (BIO) CEO & Investor Conference will be webcast live over the Internet. Emisphere's presentation will take place on Wednesd...
Feb 12, 2003
TARRYTOWN, N.Y., Feb 12, 2003 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the fourth quarter and year ended December 31, 2002. The Company also provided an update on development programs involving its proprietary oral delivery eligen™ technol...
Feb 3, 2003
TARRYTOWN, N.Y., Feb 3, 2003 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) will hold a conference call to discuss the Company's fourth quarter and year end 2002 financial results. The call will be held on Wednesday, February 12, 2003, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A telephone replay of the call will b...
Jan 2, 2003
TARRYTOWN, N.Y., Jan. 2 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that an audio feed of its corporate presentation at the J.P. Morgan H&Q Conference will be webcast live over the Internet. The conference is being held January 6th through 9th, 2003, at the Westin St. Francis Hotel in San Franc...
Dec 10, 2002
PHILADELPHIA, Dec. 10 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced positive outcomes from a human study evaluating two solid oral heparin formulations, in tablet and capsule form, in healthy male volunteers. For each solid dosage, which made use of Emisphere's eligen™...
Dec 9, 2002
PHILADELPHIA, Dec. 9 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that results of its "PROTECT" Phase III trial evaluating a liquid oral heparin were presented at the 44th annual meeting of the American Society of Hematology (ASH), being held this week in Philadelphia, by Russell D. Hull, M.B.B.S., M.Sc....
Dec 6, 2002
TARRYTOWN, N.Y., Dec. 6 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss data presented at the American Society of Hematology's annual meeting. The call will be held on Tuesday, December 10, 2002, beginning at 10:00 a.m. Eastern Time (7 a.m. Pacific). A replay of the call will be acces...
Nov 29, 2002
TARRYTOWN, N.Y., Nov. 29 /PRNewswire-FirstCall/-- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the continued streamlining of its operations, allowing the Company to focus on the broader application and outlicensing of its core eligen™ technology platform. This includes the removal of the po...
Nov 12, 2002
TORONTO, Nov. 12 /PRNewswire-FirstCall/-- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that six abstracts describing various research and development programs using Emisphere's proprietary oral drug delivery technology, which has recently been designated as eligen™, are being presented by re...
Nov 6, 2002
TARRYTOWN, N.Y., Nov. 6 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the third quarter ended September 30, 2002. The net loss for the three months ended September 30, 2002 was $13.0 million, or $0.72 per share, compared to a net loss of $17.0 million, or $0.96 per share, respe...
Oct 29, 2002
TARRYTOWN, N.Y., Oct 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's third quarter financial results for the quarter ending September 30, 2002. The call will be held on Wednesday, November 6, 2002, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacif...
Aug 6, 2002
TARRYTOWN, N.Y., Aug 6, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the second quarter ended June 30, 2002. FINANCIAL RESULTS The net loss for the three months ended June 30, 2002 was $24.9 million, or $1.39 per share, compared to a net loss of $11.6 million, or $0.65 per share, f...
Aug 1, 2002
TARRYTOWN, N.Y., Aug 1, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced it has begun an early phase clinical trial to evaluate an oral formulation of recombinant human growth hormone (rhGH). The oral formulation in the study, which combines an EMISPHERE® delivery agent with...
Aug 1, 2002
TARRYTOWN, N.Y., Aug 1, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that its corporate presentation at Adams Harkness and Hill's 21st Annual Summer Seminar will be webcast live over the internet. The conference is being held August 5th-8th at the Marriott Long Wharf in Boston, MA. Emisphere's presentation wi...
Jul 16, 2002
TARRYTOWN, N.Y., Jul 16, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's second quarter financial results for the quarter ending June 30, 2002. The call will be held on Tuesday, August 6, 2002, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A replay of the call wil...
Jun 16, 2002
SAN FRANCISCO, Jun 16, 2002 /PRNewswire-/ -- At the American Diabetes Association (ADA) 62nd Scientific Session, held this week, a researcher from Emisphere Technologies, Inc. (Nasdaq: EMIS) today presented proof-of-concept clinical results from a study conducted at Medeval Limited in Manchester, United Kingdom, which showed that an oral formul...
Jun 5, 2002
TARRYTOWN, N.Y., Jun 5, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial guidance for the second quarter and fiscal year after implementing a restructuring plan previously announced on May 22, 2002. Along with the cost savings from discontinuing all programs related to oral liquid heparin, the restructu...
Jun 4, 2002
TARRYTOWN, N.Y., Jun 4, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that its corporate presentation at the UBS Warburg Global Specialty Pharmaceuticals Conference will be webcast live over the internet. The conference is being held June 5th and 6th at the Grand Hyatt Hotel in New York City, NY. Emisphere's p...
May 22, 2002
TARRYTOWN, N.Y., May 22 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced that it has initiated a restructuring plan intended to ensure current cash balances are sufficient to continue the advancement of all existing development programs, including an improved solid form of oral heparin. Following the ...
May 15, 2002
TARRYTOWN, N.Y., May 15, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will host their annual shareholders meeting on May 16, 2002 at the Westchester Marriott in Tarrytown, NY beginning at 10:00 AM eastern time. For those shareholders who are unable to attend, a live webcast will be made available on the Company's web site at...
May 14, 2002
TARRYTOWN, N.Y., May 14, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced initial results from its Phase III study with an oral heparin formulation for the prevention of deep vein thrombosis (DVT, or blood clots) in total hip replacement surgery patients. The results did not demonstrate the superiority of oral h...
May 7, 2002
TARRYTOWN, N.Y., May 7, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the first quarter ended March 31, 2002. FINANCIAL RESULTS The net loss for the three months ended March 31, 2002 was $21.4 million or $1.20 per share, compared to a net loss of $8.3 million, or $0.47 per share, for...
Apr 25, 2002
TARRYTOWN, N.Y., Apr 25, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's first quarter financial results for the period ending March 30, 2002. The call will be held on Tuesday, May 7, 2002, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A replay of the call will be...
Feb 15, 2002
TARRYTOWN, N.Y., Feb 15, 2002 /PRNewswire/ -- Emisphere Technologies, Inc., (Nasdaq: EMIS) will be participating as a corporate presenter and as a panel participant at the Biotechnology Industry Organization's annual CEO & Investor Conference. The conference is being held next week at the Waldorf Astoria Hotel in New York City, NY. Emispher...
Feb 6, 2002
TARRYTOWN, N.Y., Feb 6, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the fourth quarter and year ended December 31, 2001. FINANCIAL RESULTS The net loss for the three months ended December 31, 2001 was $19.7 million or $1.11 per share, compared to a net loss of $4.7 million, or $0.2...
Jan 28, 2002
TARRYTOWN, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's fourth quarter and year end financial results for the period ending December 31, 2001. The call will be held on Wednesday, February 6, 2002, beginning at 2:30 p.m. Eastern time (11:30 a.m. Pacific)....
Jan 7, 2002
SAN FRANCISCO, Jan. 7 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that enrollment of 2,292 patients for the PROTECT Trial, conducted at over 120 sites worldwide has been completed. The PROTECT Trial is investigating Emisphere's lead product, an oral heparin solution formulation, for the prevention of deep vein t...
Jan 4, 2002
TARRYTOWN, N.Y., Jan 4, 2002 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that its corporate presentation to the investment community for the J.P. Morgan H & Q 20th Healthcare Conference will be webcast over the internet. Chairman and Chief Executive Officer, Michael M. Goldberg, M.D., will present on Monday, ...
Jan 3, 2002
TARRYTOWN, N.Y., Jan 3, 2002 /PRNewswire/ -- Emisphere Technologies, Inc., (Nasdaq: EMIS) announced today the appointment of Alan William Dunton, M.D., to the newly created position of President and Chief Operating Officer. Dr. Dunton joins Emisphere from The Janssen Research Foundation (JRF), a Johnson & Johnson company (NYSE: JNJ), w...
Nov 26, 2001
TARRYTOWN, N.Y., Nov 26, 2001 /PRNewswire/ -- Emisphere Technologies, Inc., (Nasdaq: EMIS) announced today that its corporate presentation to the investment community for the Robertson Stephens Medical Conference will be webcast over the internet. Chairman and Chief Executive Officer, Michael M. Goldberg, M.D., will present on Thursday, Novembe...
Nov 5, 2001
SAN FRANCISCO, Nov. 5 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that a study evaluating the oral delivery of insulin combined with one of the Company's proprietary delivery agents was selected as "one of the best" at the first international Diabetes Technology Meeting in San Francisco, CA (11/2/01-11/3/01). Th...
Oct 25, 2001
TARRYTOWN, N.Y., Oct. 25 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the third quarter and nine months ended September 30, 2001. FINANCIAL RESULTS The net loss for the three months ended September 30, 2001 was $17.0 million or $0.96 per share compared to a net loss of $2...
Oct 23, 2001
DENVER, Oct. 23 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that twelve presentations describing various aspects of the Company's proprietary delivery technology are being presented by researchers from Emisphere at the American Association of Pharmaceutical Scientists Annual Meeting and Exposition in Denver, Col...
Oct 16, 2001
TARRYTOWN, N.Y., Oct. 16 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's third quarter financial results for the period ending September 30, 2001. The call will be held on Thursday, October 25, 2001, beginning at 10:30 a.m. Eastern Time (7:30 a.m. Pacific). A replay of the call...
Sep 20, 2001
NEW YORK, Sep 20, 2001 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that its Board of Directors has authorized a share repurchase program of up to $30 million. The repurchase program is effective immediately. Emisphere Technologies, Inc. currently has 17.9 million shares outstanding and as of June 30, 2001 reporte...
Sep 7, 2001
NEW YORK, Sep 7, 2001 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today the results from three Phase I studies evaluating two of its proprietary drug delivery agents (carriers) for the oral delivery of insulin. The data, presented at an Emisphere-sponsored Investor Day held at The Plaza Hotel in New York City, demonstr...
Sep 4, 2001
TARRYTOWN, N.Y., Sep 4, 2001 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will webcast and telecast its meeting for investors on Friday, September 7, 2001. Presentations are scheduled to begin at 9:30 a.m. Eastern Time, at which time the webcast and telecast will begin. The presentations will discuss recen...
Aug 2, 2001
TARRYTOWN, N.Y., Aug. 2 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced demonstration of the oral delivery of a parathyroid hormone fragment (PTH) in multiple animal models. This study was conducted in a collaboration between scientists from Emisphere and Eli Lilly and Company (NYSE: LLY). A recombinant version of ...
Jul 31, 2001
TARRYTOWN, N.Y., July 31 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that its corporate presentation to the investment community for the Adams, Harkness & Hill Summer Seminar will be webcast live over the Internet on Thursday, August 2, 2001, at 10:00 a.m. ET. Interested investors can access a...
Jul 26, 2001
TARRYTOWN, N.Y., July 26 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the second quarter and six months ended June 30, 2001. FINANCIAL RESULTS The net loss for the three months ended June 30, 2001 was $11.6 million or $0.65 per share compared to a net loss of $3.7 million...
Jul 17, 2001
TARRYTOWN, N.Y., July 17 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's second quarter financial results for the period ending June 30, 2001 on Thursday, July 26, 2001, beginning at 10:00 a.m. Eastern time (7:00 a.m. Pacific). The live conference call dial-in num...
Jun 25, 2001
TARRYTOWN, N.Y., Jun 25, 2001 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it has initiated the dosing phase of two clinical studies evaluating its proprietary oral delivery technology with insulin. The studies are being conducted in The Netherlands and in Israel. These first human trials will consist of ...
Jun 14, 2001
TARRYTOWN, N.Y., June 14 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it has been issued United States patent number 6,242,495 covering its oral parathyroid hormone (PTH) compositions and dosage unit forms, which Emisphere is developing in its collaboration with Eli Lilly and Company (NYSE: LLY). ...
Jun 12, 2001
TARRYTOWN, N.Y., Jun 12, 2001 /PRNewswire/ -- Emisphere Technologies, Inc., (Nasdaq: EMIS) announced today that its corporate presentation to the investment community for the Goldman Sachs Healthcare Conference will be webcast live over the Internet. Chairman and Chief Executive Officer, Michael M. Goldberg, M.D., will present on Thursday, June...
May 8, 2001
TARRYTOWN, N.Y., May 8 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it has completed the dosing phase of a human clinical study to evaluate oral heparin tablets utilizing its proprietary delivery agent, SNAD (Sodium N-[10-(2 hydroxybenzoyl)amino]decanoate). SNAD is Emisphere's drug delivery agent developed for u...
May 7, 2001
TARRYTOWN, N.Y., May 7 /PRNewswire/ -- Emisphere Technologies, Inc., Chairman and Chief Executive Officer, Michael M. Goldberg, M.D., will present to the investment community for Deutsche Banc Alex. Brown's 26th Annual Health Care Conference 2001 in Baltimore, tomorrow, May 8, 2001 at 3:30 p.m. Eastern. Interested investors can a...
May 1, 2001
TARRYTOWN, N.Y., May 1 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced results for the first quarter ended March 31, 2001, following its recent transition to a calendar year financial reporting period. FINANCIAL RESULTS The net loss for the three months ended March 31, 2001 was $8.3 mil...
Apr 19, 2001
TARRYTOWN, N.Y., April 19 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's first quarter financial results for the period ending March 31, 2001, following its recent transition to a calendar year financial reporting period. The call will be held on Tuesday, May 1, 2001, beginning a...
Mar 9, 2001
TARRYTOWN, N.Y., March 9 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced it has commenced human clinical testing in the United States of oral heparin tablets utilizing its delivery agent, Sodium N-[10-(2 hydroxybenzoyl)amino]decanoate (SNAD). SNAD is Emisphere's drug delivery agent developed for use with Emisphere's...
Feb 14, 2001
TARRYTOWN, N.Y., Feb. 14 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the five months ended December 31, 2000. In January 2001, Emisphere announced that it was changing its annual financial reporting period from a fiscal year end of July 31 to a calendar year end. In connecti...
Jan 30, 2001
TARRYTOWN, N.Y., Jan. 30 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that its Board of Directors has approved a change in its annual financial reporting period from a fiscal year end of July 31 to a calendar year end. Accordingly, Emisphere's quarterly reporting periods will now end on March 31, J...
Jan 29, 2001
NEW YORK, Nov 29, 2001 /PRNewswire via COMTEX/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the results of the initial Phase I clinical study evaluating the oral delivery of cromolyn sodium with one of the Company's proprietary drug delivery agents. Cromolyn sodium, a non-steroidal anti-allergy medication, has long been con...
Jan 24, 2001
TARRYTOWN, N.Y., Jan. 24 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it has submitted an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to commence human clinical testing of oral heparin tablets utilizing its improved delivery agent, Sodium N[10-(2 hydroxybenz...
Jan 8, 2001
TARRYTOWN, N.Y., Jan. 8 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Novartis has submitted an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to commence human clinical testing in the United States of salmon calcitonin tablets for the treatment of osteopor...
Dec 7, 2000
TARRYTOWN, N.Y., Dec. 7 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the first quarter of fiscal 2001 ended October 31, 2000. FINANCIAL RESULTS The net loss for the three months ended October 31, 2000 was $3.8 million or $0.21 per share compared to a net loss of...
Dec 4, 2000
TARRYTOWN, N.Y., Dec. 4 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's first quarter financial results for fiscal 2001 on Thursday, December 7, 2000, beginning at 10:30 a.m. Eastern time (7:30 a.m. Pacific). The live conference call dial-in number is:
Nov 6, 2000
CAMBRIDGE, Mass., Nov. 6 /PRNewswire/ -- Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) and Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced a research and development collaboration to utilize Emisphere's oral drug delivery technology for Cubist's late-stage development product Cidecin™ (daptomycin for...
Sep 14, 2000
TARRYTOWN, N.Y., Sept. 14 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the fourth quarter and fiscal year ended July 31, 2000. FINANCIAL RESULTS The net loss for the three months ended July 31, 2000 was $3.6 million or $0.21 per share compared to a net loss of $...
Jun 30, 2000
WILMINGTON, Del., and TARRYTOWN, N.Y., June 30 /PRNewswire/ -- DuPont Pharmaceuticals Company, a wholly-owned independent subsidiary of DuPont (NYSE: DD) and Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced they have agreed to terms on a development and marketing agreement for oral formulations of heparin and low molecular weight hep...
Jun 13, 2000
Indianapolis, IN and Tarrytown, NY, June 13, 2000 --- Eli Lilly and Company (NYSE: LLY) and Emisphere Technologies, Inc. (NASDAQ: EMIS) today announced that they have executed a follow-on development agreement to their previously announced research and option agreement to develop oral formulations of FortéoÔ (recombinant parathyroid hormo...
Jun 7, 2000
TARRYTOWN, N.Y., June 7 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the publication of two studies evidencing the successful treatment of deep vein thrombosis (DVT) in animal models of deep venous thrombosis using their oral SNAC/heparin and oral SNAD/LMWH. The manuscript entitled "Orally Administe...
Jun 6, 2000
TARRYTOWN, N.Y., June 6 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the fiscal 2000 third quarter and nine-months ended April 30, 2000. FINANCIAL RESULTS The net loss for the three months ended April 30, 2000 was $4.3 million or $0.27 per share compared to a ne...
Apr 19, 2000
TARRYTOWN, N.Y., April 19 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced preliminary clinical data confirming pre- clinical findings that its technology can effect adequate oral heparin delivery in a capsule dosage form. In this study a solid dosage form of heparin and Emisphere's proprietary carrier...
Mar 16, 2000
TARRYTOWN, N.Y., March 16 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it is initiating clinical testing of a solid oral dosage form of heparin. The study is a Phase I safety and tolerability study in healthy subjects and is being conducted in the United Kingdom. In animal mo...
Mar 16, 2000
TARRYTOWN, N.Y., March 16 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the fiscal 2000 second quarter and six months ended January 31, 2000. FINANCIAL HIGHLIGHTS The net loss for the three months ended January 31, 2000 was $9.2 million or $0.63 per share com...
Mar 14, 2000
TARRYTOWN, N.Y., March 14 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the completion of an offering of 2,750,000 shares of common stock at a price of $72.75 per share. Chase H&Q, Deutsche Banc Alex. Brown, Warburg Dillon Read LLC, and Adams, Harkness & Hill, Inc. served as underwriters for th...
Mar 9, 2000
TARRYTOWN, N.Y., March 9 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), today announced it has commenced human clinical testing in the United States of oral heparin tablets utilizing its delivery agent, Sodium N-[10-(2 hydroxybenzoyl)amino]decanoate (SNAD). SNAD is Emisphere's drug delivery agent developed for use with Emisphere's...
Mar 2, 2000
BASEL, Switzerland and TARRYTOWN, N.Y., March 2 /PRNewswire/ -- Novartis Pharma AG (Zurich: NOV) and Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Novartis will extend its collaboration with Emisphere for the oral delivery of a second Novartis compound. The two companies will collaborate to select a second drug compound from...
Feb 17, 2000
TARRYTOWN, N.Y., Feb. 17 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Novartis has agreed to execute its option to acquire an exclusive license to develop and commercialize oral calcitonin, a drug used for the treatment of osteoporosis. Oral calcitonin will utilize Emisphere's proprietary drug delivery technolog...
Feb 14, 2000
TARRYTOWN, N.Y., Feb. 14 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the filing of a registration statement with the Securities and Exchange Commission for an offering of 2,500,000 shares of its common stock. Emisphere will also grant to the underwriters an option to purchase an additional 375,000 shares of common s...
Jan 11, 2000
BASEL, Switzerland and TARRYTOWN, N.Y., Jan. 11 /PRNewswire/ -- Novartis Pharma AG (Zurich: NOV) and Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced positive results from a Phase I study conducted by Novartis of a solid oral dosage form of the protein calcitonin incorporating Emisphere's proprietary drug delivery technology. Study resu...
Dec 15, 1999
TARRYTOWN, N.Y., Dec. 15 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the fiscal 2000 first quarter ended October 31, 1999. The Company reported contract research revenues of $625,000 for the first quarter of fiscal 2000, compared to $3.6 million in the same period in fiscal 1999...
Dec 15, 1999
TARRYTOWN, N.Y., Dec. 15 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it has finalized its Phase III protocol. The protocol represents the culmination of a process of trial design that incorporated input from Emisphere's Heparin Advisory Board, Quintiles Transnational, Inc., and the Food and Drug Administration (...
Nov 18, 1999
Tarrytown, NY, November 18, 1999 --- Emisphere Technologies, Inc. (Nasdaq:) was selected by Deloitte & Touche as a winner in their 1999 Technology Fast 500 award. In the national ranking of the 500 fastest growing companies selected by Deloitte & Touche, Emisphere placed 14th . This follows the number 1 ranking amongst the 50 fastest-grow...
Oct 28, 1999
TARRYTOWN, N.Y., Oct. 28 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the completion of an offering of 2,000,000 shares of common stock, at a price of $11 per share. Hambrecht & Quist LLC served as underwriter for the offering. Emisphere received approximately $20.4 million after underwriting expenses. Proce...
Sep 23, 1999
TARRYTOWN, N.Y., Sept. 23 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced financial results for the fourth quarter and fiscal year ended July 31, 1999. The Company reported contract research revenues of $625,000 for the three months ended July 31, 1999, compared to $4.3 million in the same period in 1998. For the f...
Sep 23, 1999
Tarrytown, NY, September 23, 1999 --- Emisphere Technologies, Inc. (Nasdaq:) was honored last night at the 1999 New York Technology Fast 50 Awards. This program recognizes the 50 fastest-growing technology-based companies in New York City, Westchester and Rockland Counties, based on percentage of revenues from 1994-1998. Emisphere was ranked 1 out ...
Sep 8, 1999
TARRYTOWN, N.Y., Sept. 8 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Novartis initiated clinical testing of a solid oral dosage form of one of their compounds using Emisphere's oral drug delivery technology. The study is a Phase I safety, tolerability and pharmacokinetic study in healthy subjects and is being co...
Aug 24, 1999
Tarrytown, NY, August 24, 1999 - Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it has met with the Gastrointestinal and Coagulation Drug Products Division of the Food and Drug Administration (FDA) and based on information supplied by Emisphere, the FDA has indicated that the data generated supported moving forward into Phase III ...
Aug 19, 1999
Tarrytown, NY, August 19, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced that its Phase II trial results evaluating multiple assessments of safety and activity in patients undergoing hip replacement surgery were presented today at the XVIIth Congress of the International Society of Thrombosis and Haemostasis held in Washington, D.C....
Aug 17, 1999
To be presented at the XVIIth Congress of the International Society of Thrombosis and Haemostasis-August 19, 1999 Tarrytown, NY August 17, 1999 - Emisphere Technologies, Inc. (Nasdaq: EMIS) is pleased to announce that Scott D. Berkowitz, MD, FACP, of the Divisions of Hematology and Cardiology at Duke University, will present the results of Emispher...
Jul 6, 1999
Tarrytown, NY, July 6, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it has agreed with Elan Corporation, plc (NYSE: ELN) to restructure their 50-50 joint venture to develop and market oral forms of heparin. Under terms of the agreement, Emisphere will now fully own the technology and marketing and product rights to the...
Jun 11, 1999
Tarrytown, NY, June 11, 1999 --- Emisphere Technologies, Inc. (NASDAQ: EMIS) today reported financial results for the third quarter and nine months ended April 30, 1999. Contract research revenues for the third quarter ended April 30, 1999, were $1.5 million, as compared to $6.5 million reported in the third quarter of 1998. During the third ...
Apr 13, 1999
Tarrytown, NY, April 13, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Charles H. Abdalian, Jr. has joined the Company as Chief Financial Officer, a newly created position, and that Steven M. Dinh, Sc.D. has been hired as Vice President of Research for Emisphere Technologies. Both individuals will be reporting to Michae...
Mar 13, 1999
Tarrytown, NY and Dublin, Ireland, March 17, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported financial results for the second quarter and six months ended January 31, 1999. For the second quarter of 1999, Emisphere reported a net loss of approximately $5.1 million, or $0.45 per share, as compared to a net loss of approxim...
Feb 25, 1999
Tarrytown, NY, February 25, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported on a number of key events in their oral heparin program. First, the manufacturing process for the Emisphere carrier has been successfully taken to a larger scale with greater overall purity, and significantly lower cost than the pilot scale process. Seco...
Jan 13, 1999
Tarrytown, NY and Dublin, Ireland, January 13, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will form a new subsidiary company to explore the development of a novel drug design technology. The Company will initially investigate the use of the technology for the treatment of drug-resistant microbial infections. The Ch...
Jan 11, 1999
Hawthorne, NY and Dublin, Ireland, January 11, 1999 --- Emisphere Technologies, Inc. (Nasdaq: NMS: EMIS) and Elan Corporation, plc (NYSE: ELN) announced that the preliminary results of the Phase II oral heparin study indicated that the oral heparin formulations were comparable to injectable heparin in thc prevention of deep venous thrombosis (DVT)...
Oct 27, 1998
Hawthorne, NY, October 27, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported fourth quarter and year end financial results for the period ended July 31, 1998. Net loss for the fourth quarter of 1998 was $3.4 million, or $0.31 per diluted share, compared to a net loss of $1.8 million, or $0.19 per share, in the fourth quarte...
Sep 3, 1998
Indianapolis, IN, and Tarrytown, NY September 3, 1998 --- Eli Lilly & Co. (NYSE: LLY) and Emisphere Technologies, Inc. (Nasdaq: NMS: EMIS) announced today that Lilly has formally selected a proprietary Emisphere carrier for clinical testing of the oral delivery of an important Lilly protein for the treatment of Osteoporosis. Preparations for cl...
Aug 5, 1998
Tarrytown, NY, August 5, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) announced today that Emisphere and Elan Corporation plc have contributed $10 million ($5 million each) to their 50-50 joint venture to develop oral formulations of heparin compounds. The joint venture is currently conducting a Phase II trial for an oral formulation of...
Jun 15, 1998
Hawthorne, NY, June 15, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported net income of $1.3 million, or $0.10 per diluted share, for the third quarter ended April 30, 1998, compared to a net loss of $2.1 million, or $0.22 per share, for the third quarter last year. The Company also reported a net loss of $3.7 million, or $0.35 pe...
May 27, 1998
Hawthorne, NY, May 27, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today it has initiated a Phase II clinical study for its oral heparin product for the prevention of deep vein thrombosis. The study will have three arms of approximately 40 patients each who have undergone surgery for hip replacement, and will be conducted at up t...
May 20, 1998
Hawthorne, NY, May 20, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Barry B. Kanarek, M.D., Ph.D., has joined the Company as Senior Vice President of Clinical Affairs, a newly created position. Dr. Kanarek will be responsible for the directing, planning, executing and interpreting of clinical trials/research and data co...
May 4, 1998
Hawthorne, NY, May 4, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the closing of a $13.5 million private placement of 5% senior convertible notes. Emisphere plans to use the proceeds of the private placement for general purposes, including funding its share of the clinical trials for its oral heparin product. The note...
Mar 19, 1998
Hawthorne, NY, March 19, 1998 --- Emisphere Technologies, Inc. (Nasdaq: NMS:EMIS) today reported a net loss of approximately $2.6 million, or $0.25 per share, for the second quarter ended January 31, 1998, as compared to net loss of approximately $2.4 million, or $0.26 per share, for the same period last year. The Company also reported a net loss o...
Mar 16, 1998
Hawthorne, NY and Indianapolis IN, March 16, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) and Eli Lilly & Co. (NYSE:LLY) announced today that Lilly has executed two license agreements with Emisphere to utilize Emisphere's proprietary oral delivery technology to create oral forms of two of Lilly's therapeutic proteins. One compound i...
Jan 14, 1998
Hawthorne, NY and Dublin, Ireland (January 14, 1998) --- Emisphere Technologies, Inc. (Nasdaq: EMIS) and Elan Corporation, plc (NYSE: ELN) announced today on behalf of their joint venture the successful completion of two Phase I clinical trials for its oral formulation of heparin. These are the third and fourth Phase I clinical trials for the oral ...
Page:
1
2
...
28
Next Last
 

= add release to Briefcase

FOLLOW US